U.S. patent application number 14/067505 was filed with the patent office on 2014-06-12 for sirna silencing of genes expressed in cancer.
This patent application is currently assigned to Alnylam Pharmaceuticals, Inc.. The applicant listed for this patent is Alnylam Pharmaceuticals, Inc.. Invention is credited to James Heyes, Lloyd B. Jeffs, Adam Judge, Ian MacLachlan, Lorne Palmer, Vandana Sood.
Application Number | 20140161894 14/067505 |
Document ID | / |
Family ID | 40722273 |
Filed Date | 2014-06-12 |
United States Patent
Application |
20140161894 |
Kind Code |
A1 |
MacLachlan; Ian ; et
al. |
June 12, 2014 |
SIRNA SILENCING OF GENES EXPRESSED IN CANCER
Abstract
The present invention provides nucleic acid-lipid particles
comprising siRNA molecules that silence genes expressed in cancer
(e.g., Eg5, EGFR or XIAP) and methods of using such nucleic
acid-lipid particles to silence Eg5, EGFR or XIAP gene
expression.
Inventors: |
MacLachlan; Ian; (Mission,
CA) ; Judge; Adam; (Vancouver, CA) ; Sood;
Vandana; (Vancouver, CA) ; Heyes; James;
(Vancouver, CA) ; Jeffs; Lloyd B.; (Delta, CA)
; Palmer; Lorne; (Vancouver, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Alnylam Pharmaceuticals, Inc. |
Cambridge |
MA |
US |
|
|
Assignee: |
Alnylam Pharmaceuticals,
Inc.
Cambridge
MA
|
Family ID: |
40722273 |
Appl. No.: |
14/067505 |
Filed: |
October 30, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11807872 |
May 29, 2007 |
8598333 |
|
|
14067505 |
|
|
|
|
60808859 |
May 26, 2006 |
|
|
|
60817556 |
Jun 28, 2006 |
|
|
|
Current U.S.
Class: |
424/498 ;
435/366; 435/375; 514/44A; 536/24.5 |
Current CPC
Class: |
A61K 31/575 20130101;
C12N 15/113 20130101; C12Y 603/02019 20130101; C12N 15/1138
20130101; C12N 15/1135 20130101; A61K 31/7088 20130101; C12N
15/1137 20130101; Y10T 428/2982 20150115; C12N 2310/3515 20130101;
C12N 2310/14 20130101 |
Class at
Publication: |
424/498 ;
514/44.A; 435/375; 435/366; 536/24.5 |
International
Class: |
C12N 15/113 20060101
C12N015/113; A61K 31/7088 20060101 A61K031/7088; A61K 31/575
20060101 A61K031/575 |
Claims
1. A nucleic acid-lipid particle comprising: an siRNA molecule that
silences expression a gene expressed in cancer, said gene selected
from the group consisting of Eg5, EGFR, XIAP, and combinations
thereof; a cationic lipid; a non-cationic lipid; and a conjugated
lipid that inhibits aggregation of said particle.
2. The nucleic acid-lipid particle of claim 1, wherein said nucleic
acid-lipid particle comprises an siRNA molecule comprising at least
one sequence set forth in any one of Tables 1-9.
3. (canceled)
4. (canceled)
5. (canceled)
6. The nucleic acid-lipid particle of claim 1, wherein said
cationic lipid is a member selected from the group consisting of
N,N-dioleyl-N,N-dimethylammonium chloride (DODAC),
N,N-distearyl-N,N-dimethylammonium bromide (DDAB),
N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
(DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium
chloride (DOTMA), and N,N-dimethyl-2,3-dioleyloxy)propylamine
(DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA),
1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLendMA), and a
mixture thereof.
7. The nucleic acid-lipid particle of claim 1, wherein said
cationic lipid is DLinDMA.
8. The nucleic acid-lipid particle of claim 1, wherein said
non-cationic lipid is a member selected from the group consisting
of dioleoylphosphatidylethanolamine (DOPE),
palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine
(EPC), distearoylphosphatidylcholine (DSPC),
palmitoyloleyolphosphatidylglycerol (POPG), dipalmitoyl
phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine
(DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE),
16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE,
palmitoyloleoyl-phosphatidylethanolamine (POPE),
1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol,
and a mixture thereof.
9. The nucleic acid-lipid particle of claim 1, wherein said
non-cationic lipid is DSPC.
10. The nucleic acid-lipid particle of claim 1, wherein the
conjugated lipid that inhibits aggregation of particles is a
polyethyleneglycol (PEG)-dialkyloxypropyl (PEG-DAA) conjugate
selected from the group consisting of a PEG-dilauryloxypropyl
(C.sub.12), a PEG-dimyristyloxypropyl (C.sub.14), a
PEG-dipalmityloxypropyl (C.sub.16), and a PEG-distearyloxypropyl
(C.sub.18).
11. The nucleic acid-lipid particle of claim 10, wherein the
PEG-DAA conjugate is a PEG-dimyristyloxypropyl (C.sub.14).
12. The nucleic acid-lipid particle of claim 1, wherein said
cationic lipid comprises from about 30 mol % to about 50 mol % of
the total lipid present in said particle.
13. The nucleic acid-lipid particle of claim 1, wherein said
non-cationic lipid comprises from about 5 mol % to about 90 mol %
of the total lipid present in said particle.
14. The nucleic acid-lipid particle of claim 10, wherein said
PEG-DAA conjugate comprises from 1 mol % to about 20 mol % of the
total lipid present in said particle.
15. The nucleic acid-lipid particle of claim 1, further comprising
cholesterol.
16. The nucleic acid-lipid particle of claim 15, wherein the
cholesterol comprises from about 10 mol % to about 60 mol % of the
total lipid present in said particle.
17. (canceled)
18. (canceled)
19. (canceled)
20. The nucleic acid-lipid particle of claim 1, wherein the nucleic
acid is fully encapsulated in said nucleic acid-lipid particle.
21. The nucleic acid-lipid particle of claim 1, wherein said
particle has a nucleic acid:lipid ratio of from about 0.01 to about
0.2.
22. The nucleic acid-lipid particle of claim 1, wherein said
particle has a median diameter of less than about 150 nm.
23. A composition comprising the nucleic acid-lipid particle of
claim 2 and a pharmaceutically acceptable carrier.
24. A method of introducing an siRNA that silences expression of a
Eg5, EGFR or XIAP gene into a cell, said method comprising:
contacting said cell with a nucleic acid-lipid particle comprising
a cationic lipid; a non-cationic lipid; a conjugated lipid that
inhibits aggregation of particles; and said siRNA.
25.-33. (canceled)
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/807,872, filed May 29, 2007 (pending), and
claims the benefit of U.S. Provisional Patent Application Nos.
60/808,859, filed May 26, 2006, and 60/817,556 filed Jun. 28, 2006,
the disclosures of which are hereby incorporated by reference in
their entirety for all purposes.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted via EFS-Web and is hereby incorporated by
reference in its entirety. Said ASCII copy, created on Oct. 29,
2013, is named 24607US_sequencelisting.txt, and is 4,224,563 bytes
in size.
BACKGROUND OF THE INVENTION
[0003] Cell proliferation and programmed cell death play important
roles in the growth and development of an organism. In
proliferative diseases such as cancer, the processes of cell
proliferation and/or programmed cell death are often perturbed. For
example, a cancer cell may have unregulated cell division through
either the overexpression of a positive regulator of the cell cycle
or the loss of a negative regulator of the cell cycle, perhaps by
mutation. Alternatively, a cancer cell may have lost the ability to
undergo programmed cell death through the overexpression of a
negative regulator of apoptosis. Therefore, there is a need to
develop new therapeutic agents that will restore the processes of
checkpoint control and programmed cell death to cancerous
cells.
[0004] RNA interference (RNAi) is an evolutionarily conserved
process in which recognition of double-stranded RNA (dsRNA)
ultimately leads to posttranscriptional suppression of gene
expression. This suppression is mediated by short double stranded
RNA (dsRNA), also called small interfering RNA (siRNA), which
induces specific degradation of mRNA through complementary base
pairing. In several model systems, i.e., mostly lower order
animals, this natural response has been developed into a powerful
tool for the investigation of gene function (Elbashir S M, et al.,
Genes Dev, 2001, 15:188-200; Hammond S M, et al., Nat Rev Genet.,
2001, 2:110-119). More recently it was discovered that introducing
synthetic 21-nucleotide dsRNA duplexes into mammalian cells could
efficiently silence gene expression. Although the precise mechanism
is still unclear, RNAi offers a new way to inactivate genes of
interest. In particular, for the treatment of neoplastic disorders
(cancer), RNAi provides a potential new approach to modulate (e.g.,
reduce) the expression of certain genes, e.g., an anti-apoptotic
molecule, a growth factor, a growth factor receptor, a mitotic
spindle protein, a cell cycle protein, an angiogenic factor, an
oncogene, an intracellular signal transducer, a molecular
chaperone, and combinations thereof.
[0005] One such target is the Eg5 gene which produces the
microtubule-associated protein, Eg5 (Kapoor, T. M., et al., J. Cell
Biol., 2001, 154, 1125-1133; Garrett, S. et al., Curr Biol., 2003,
13, R810-812; Cassimeris, L., et al., Curr Issues Mol Biol., 2003,
5, 99-112; Houliston, E., et al., Dev. Biol. 1994, 164, 147-159).
Generally, due to the clinical success seen with antimitotics in
cancer therapy (e.g. taxanes), other proteins that that are also
involved in the mitotic machinery, such as Eg5, have become
desirable targets as next generation anti-cancer therapeutics. The
mitotic kinesin, Eg5, contains an N-terminal motor domain which
generates force along the microtubule, moving Eg5 to the
microtubule plus end. During interphase in most epithelial cells,
the plus ends of microtubules are oriented toward the plasma
membrane while the minus ends are facing toward the nucleus. Upon
entry into mitosis, microtubule plus ends reorient toward the
chromosomes, while the minus ends are anchored at the spindle
poles, forming a bipolar spindle. The homotetrameric structure of
Eg5 has its motor domains arranged at two ends of a dumbbell such
that it can bind and push apart spindle microtubules and generate
and outward-directed force pushing spindle poles apart (Sawin, K.
E., et al., Prod Natl. Acad. Sci. USA, 1995, 92, 4289-4293; Kapoor,
T. M., et al., J Cell Biol., 2000, 150, 975-988; Gaglio, T., et
al., J Cell Biol., 1996, 135, 399-414). Thus, Eg5 is critical for
proper spindle formation during the mitotic process. Disruption of
the process leads to activation of spindle assembly checkpoint, the
major cell cycle control mechanism which prevents the cell
undergoing mitosis to progress to anaphase and leads to cell cycle
arrest. Inhibition of the production of the Eg5 protein, which is
only expressed during mitosis, results in the induction of cancer
cell apoptosis through a unique mechanism. In view of the important
role of Eg5 has in the mitotic process, Eg5 has become an
attractive therapeutic target for rapidly dividing cells, in
particular, in cancer therapy.
[0006] The first small molecule inhibitors of Eg5 was identified in
a phenotype-based screen and has been termed Monastrol, because of
the formation of monoastral spindles due to Eg5 inhibition seen in
cells treated with Monastrol (Mayer, T. U., et al., Science, 1999,
286, 971-974). Other small molecule inhibitors of Eg5 have been
discovered since and are currently under development (Sakowicz, R.,
et al., Cancer Res., 2004, 64, 3276-3280; Hotha, S. et al., Angew
Chem. Intl. Ed. Engl., 2003, 42, 2379-2382). However, recent
literature publications suggest that certain cancer cell lines,
e.g., HT-29 colorectal cancer cells, are resistant toward small
molecule Eg5 inhibitors, and thus suggest that small molecule Eg5
inhibitors may have be of more limited clinical use than previously
thought.
[0007] A second target is the EGFR gene that encodes for the
epidermal growth factor receptor (EGFR), a glycoprotein with a
molecular weight of 170,000 to 180,000. EGFR is an intrinsic
tyrosine-specific protein kinase, which is stimulated upon
epidermal growth factor (EGF) binding. The known downstream
effectors of EGFR include PI3-K, RAS-RAF-MAPK P44/P42, and protein
kinase C signaling pathways. EGFR signaling involved in cell
growth, angiogenesis, DNA repair, and autocrine growth regulation
in a wide spectrum of human cancer cells (Wakeling A E., Curr Opin
Pharmacol 2002, 2:382-387). Therefore, it has recently emerged as
an innovative target for the development of new cancer therapy.
Recently, a monoclonal antibody against EGFR called cetuximab has
been developed. It has shown excellent clinical effects for the
treatment of lung and head and neck cancer in a clinical trial in
humans (Shin et al., Clin Cancer Res, 2001, 7:1204-1213). Other
small chemical inhibitors, such as ZD-1839 have also been developed
and demonstrated anti-tumor effects in in vitro and in vivo
(Shawver L K, et al., Cancer Cell 2002, 1:117-123). However,
clinical use of ZD-1839 in humans has not been very successful.
(Baselga Eur J Cancer 2001, 37:S16-22).
[0008] A third target is the XIAP (X-linked inhibitor of apoptosis
protein) which is a member of the mammalian IAP gene family and
encodes for the X-linked IAP (XIAP) protein. The anti-apoptotic
function of XIAP is executed, at least in part, by inhibition of
caspase-3 and caspase-7, two principal effectors of apoptosis. XIAP
protein plays a critical role in regulating programmed cell death
by suppressing activation of downstream caspase-3 and caspase-7.
Interestingly, in pre-cancerous and cancerous cells, it is believed
that expression or overexpression of XIAPs makes it difficult for
cancer cells to eliminate themselves, instead allowing them to
proliferate, metastasize and accumulate additional oncogenic
mutations. Inhibition of XIAP activity using anti-sense
oligonucleotides has demonstrates anti-tumor activity in human
tumor xenograft animal model.
[0009] In view of the above, there is a need for compositions and
methods for modulating the expression of genes involved in cancer.
The present invention addresses these and other needs.
SUMMARY OF THE INVENTION
[0010] The present invention provides compositions comprising siRNA
molecules that target genes expressed in cancer and methods of
using such compositions to silence expression of such genes.
[0011] One embodiment of the invention provides a nucleic
acid-lipid particle comprising an siRNA molecule that targets a
gene expressed in cancer. In some embodiments, the gene is selected
from an anti-apoptotic molecule, a growth factor, a growth factor
receptor, a mitotic spindle protein, a cell cycle protein, an
angiogenic factor, an oncogene, an intracellular signal transducer,
a molecular chaperone, and combinations thereof. In some
embodiments, the lipid portion of the particle comprises a cationic
lipid and a non-cationic lipid. In some embodiments, the nucleic
acid-lipid particle further comprises a conjugated lipid that
prevents aggregation of the particles and/or a sterol (e.g.,
cholesterol).
[0012] Another embodiment of the invention provides a nucleic
acid-lipid particle that targets expression of the Eg5, EGFR or
XIAP gene. The nucleic acid-lipid particle comprises an siRNA
molecule that silences expression of the Eg5, EGFR or XIAP gene; a
cationic lipid; a non-cationic lipid; and a conjugated lipid that
inhibits aggregation of particles. The siRNA molecules may comprise
at least one sequence set forth in Tables 1-9 (i.e., Tables 1-2 and
7 for Eg5; Tables 3-4 and 8 for EGFR; or Tables 5-6 and 9 for
XIAP). In some embodiments, nucleic acid-lipid particles comprise
at least 2, 3, 4, 5, or 6 of the sequences set forth in Tables 1-2
and 7 for Eg5; Tables 3-4 and 8 for EGFR; or Tables 5-6 and 9 for
XIAP. In some embodiments,
[0013] The cationic lipid may be, e.g.,
N,N-dioleyl-N,N-dimethylammonium chloride (DODAC),
N,N-distearyl-N,N-dimethylammonium bromide (DDAB),
N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
(DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium
chloride (DOTMA), and N,N-dimethyl-2,3-dioleyloxy)propylamine
(DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), and
1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLendMA), or mixtures
thereof. The cationic lipid may comprise from about 2 mol % to
about 60 mol %, about 5 mol % to about 45 mol %, about 5 mol % to
about 15 mol %, about 30 mol % to about 50 mol % or about 40 mol %
to about 50 mol % of the total lipid present in the particle.
[0014] The non-cationic lipid may be an anionic lipid or a neutral
lipid including, but not limited to, a non-cationic lipid is a
member selected from the group consisting of
dioleoylphosphatidylethanolamine (DOPE),
palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine
(EPC), distearoylphosphatidylcholine (DSPC),
palmitoyloleyolphosphatidylglycerol (POPG), dipalmitoyl
phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine
(DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE),
16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE,
palmitoyloleoyl-phosphatidylethanolamine (POPE),
1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE),
1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE),
cholesterol, or mixtures thereof. The non-cationic lipid comprises
from about 5 mol % to about 90 mol % or about 20 mol % to about 85
mol % of the total lipid present in the particle.
[0015] The conjugated lipid that inhibits aggregation of particles
may be a polyethyleneglycol (PEG)-lipid conjugate, a polyamide
(ATTA)-lipid conjugate, a cationic-polymer-lipid conjugates (CPLs),
or mixtures thereof. In one preferred embodiment, the nucleic
acid-lipid particles comprise either a PEG-lipid conjugate or an
ATTA-lipid conjugate together with a CPL. The conjugated lipid that
inhibits aggregation of particles may comprise a
polyethyleneglycol-lipid including, e.g., a PEG-diacylglycerol
(DAG), a PEG dialkyloxypropyl (DAA), a PEG-phospholipid, a
PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate may
be PEG-dilauryloxypropyl (C12), a PEG-dimyristyloxypropyl (C14), a
PEG-dipalmityloxypropyl (C16), and a PEG-distearyloxypropyl (C18).
In some embodiments, the conjugated lipid that inhibits aggregation
of particles has the formula: A-W--Y, wherein: A is a lipid moiety;
W is a hydrophilic polymer; and Y is a polycationic moiety. W may
be a polymer selected from the group consisting of
polyethyleneglycol (PEG), polyamide, polylactic acid, polyglycolic
acid, polylactic acid/polyglycolic acid copolymers or combinations
thereof, said polymer having a molecular weight of about 250 to
about 7000 daltons. In some embodiments, Y has at least 4 positive
charges at a selected pH. In some embodiments, Y may be lysine,
arginine, asparagine, glutamine, derivatives thereof and
combinations thereof. The conjugated lipid that prevents
aggregation of particles may be about 0 mol % to about 20 mol %,
about 1 mol % to about 15 mol %, about 4 mol % to about 10 mol %,
or about 2 mol % of the total lipid present in said particle.
[0016] In some embodiments, the nucleic acid-lipid particle further
comprises cholesterol at, e.g., about 0 mol % to about 10 mol %,
about 2 mol % to about 10 mol %, about 10 mol % to about 60 mol %
or about 20 mol % to about 45 mol % of the total lipid present in
the particle.
[0017] In a specific embodiment of the invention, the nucleic
acid-lipid particle comprises 48% cholesterol; 10% DSPC; 2%
PEG-cDMA; and 40% DLinDMA.
[0018] In some embodiments, the siRNA in the nucleic acid-lipid
particle is not substantially degraded after exposure of the
particle to a nuclease at 37.degree. C. for at least 20, 30, 45, or
60 minutes; or after incubation of the particle in serum at
37.degree. C. for at least 30, 45, or 60 minutes, 2, 3, 4, 5, 6, 7,
8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36
hours.
[0019] In some embodiments, the siRNA is fully encapsulated in the
nucleic acid-lipid particle. In some embodiments, the siRNA is
complexed to the lipid portion of the particle.
[0020] The present invention further provides pharmaceutical
compositions comprising the nucleic acid-lipid particles described
herein and a pharmaceutically acceptable carrier.
[0021] The nucleic acid-lipid particles of the present invention
are useful for the therapeutic delivery of nucleic acids comprising
an interfering RNA sequence (i.e., an siRNA sequence that targets
expression of an Eg5, EGFR or XIAP gene. In particular, it is an
object of this invention to provide in vitro and in vivo methods
for treatment of a disease in a mammal by downregulating or
silencing the transcription and translation of a target nucleic
acid sequence of interest. In these methods, an interfering RNA is
formulated into a nucleic acid-lipid particle, and the particles
are administered to patients requiring such treatment.
Alternatively, cells are removed from a patient, the interfering
RNA delivered in vitro, and reinjected into the patient. In one
embodiment, the present invention provides for a method of
introducing a nucleic acid into a cell by contacting a cell with a
nucleic acid-lipid particle comprised of a cationic lipid, a
non-cationic lipid, a conjugated lipid that inhibits aggregation,
and an interfering RNA.
[0022] In one embodiment, at least 1%, 2%, 4%, 6%, 8%, 10%, 12%.
14%. 16% or 18% of the total injected dose of the nucleic
acid-lipid particles is present in plasma 1, 2, 4, 6, 8, 12, 16,
18, or 24 hours after injection. In other embodiments, more than
20%, 30%, 40% and as much as 60%, 70% or 80% of the total injected
dose of the nucleic acid-lipid particles is present in plasma 1, 4,
6, 8, 10, 12, 20, or 24 hours after injection. In one embodiment,
the effect of an interfering RNA (e.g., downregulation of the
target sequence) at a site proximal or distal to the site of
administration is detectable at 12, 24, 48, 72, or 96 hours, 6, 8,
10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after
administration of the nucleic acid-lipid particles. In one
embodiment, downregulation of expression of the target sequence is
detectable at 12, 24, 48, 72, or 96 hours, 6, 8, 10, 12, 14, 16,
18, 19, 20, 22, 24, 26, or 28 days after administration. In some
embodiments, downregulation of Eg5, EGFR or XIAP gene is detected
by detecting mRNA or protein levels in a biological sample from the
mammal. In some embodiments, downregulation of expression of a Eg5,
EGFR or XIAP sequence is detected by measuring the cell viability
or the induction of apoptosis of cells in a biological sample from
the mammal.
[0023] The particles are suitable for use in intravenous nucleic
acid transfer as they are stable in circulation, of a size required
for pharmacodynamic behavior resulting in access to extravascular
sites and target cell populations. The invention also provides for
pharmaceutically acceptable compositions comprising a nucleic
acid-lipid particle.
[0024] Another embodiment of the present invention provides methods
for in vivo delivery of interfering RNA (e.g., interfering RNA that
silences expression of an Eg5, EGFR or XIAP gene). A nucleic
acid-lipid particle comprising a cationic lipid, a non-cationic
lipid, a conjugated lipid that inhibits aggregation of particles,
and interfering RNA is administered (e.g., intravenously,
intramuscularly, or subcutaneously) to a subject (e.g., a mammal
such as a human or a rodent).
[0025] A further embodiment of the present invention provides a
method of treating a disease or disorder in a mammalian subject. A
therapeutically effective amount of a nucleic acid-lipid particle
comprising a cationic lipid, a non-cationic lipid, a conjugated
lipid that inhibits aggregation of particles, and interfering RNA
(e.g., interfering RNA that silences expression of a Eg5, EGFR or
XIAP gene) is administered to the mammalian subject (e.g., a rodent
such as a mouse, a primate such as a human, a chimpanzee, or a
monkey). In some embodiments, the mammalian subject has a cell
proliferative disorder. In certain aspects of this embodiment, the
mammalian subject has a said cell proliferative disorder is
selected from the group consisting of neoplasia (cancer),
hyperplasias, restenosis, cardiac hypertrophy, immune disorders and
inflammation. Preferably, said cell proliferative disorder is a
neoplastic disorder, i.e., cancer. In some embodiments, the cancer
includes, but is not limited to papilloma, blastoglioma, Kaposi's
sarcoma, melanoma, lung cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, astrocytoma, head cancer, neck cancer,
bladder cancer, breast cancer, lung cancer, colorectal cancer,
thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular
carcinoma, leukemia, lymphoma, Hodgkin's disease, osteosarcoma,
testicular cancer, and Burkitt's disease.
[0026] The invention further provides siRNA molecules having the
sequences set forth in any one of Tables 1-9. In some embodiments,
the siRNA molecules comprise modified nucleotides. The siRNA
molecules comprising modified nucleotides are capable of silencing
expression of a target sequence and are less immunostimulatory than
a corresponding unmodified siRNA sequence. In some embodiments,
less than about 20%, 15%, 10%, 5%, or 2% of the nucleotides in the
siRNA comprise modified nucleotides. In some embodiments, the
modified nucleotide is selected from a 2'-O-methyl (2'OMe)
pyrimidine and a 2'OMe purine (e.g., a 2'OMe-guanosine, a
2'OMe-uridine, and a 2'OMe-adenosine). In some embodiments, the
modified nucleotide is not 2'OMe-cytosine. In some embodiments, the
modified nucleotides are present in one strand of the siRNA (e.g.,
in the sense strand). In some embodiments the corresponding
unmodified siRNA sequence comprises at least one 5'-GU-3' motif. In
some embodiments, the at least one 5'-GU-3' motif is in the sense
strand of the unmodified siRNA sequence. In some embodiments, the
double-stranded sequence comprises a hairpin loop structure.
[0027] The invention also provides compositions comprising the
siRNA molecules described herein and a pharmaceutically acceptable
carrier.
[0028] These and other embodiments of the invention are further
described in the detailed description that follows.
BRIEF DESCRIPTION OF THE DRAWINGS
[0029] FIG. 1 illustrates data demonstrating RNAi activity of a Eg5
siRNA panel (at 1, 5, and 25 nM concentration) complexed with
lipofectamine in HeLa cells (human).
[0030] FIG. 2 illustrates data demonstrating RNAi activity of a Eg5
siRNA panel (at 1, 5, and 25 nM concentration) complexed with
lipofectamine in Neuro2A cells (mouse).
[0031] FIG. 3 illustrates data demonstrating RNAi activity of
selected SNALP formulated Eg5 siRNA sequences in Neuro2A cells.
[0032] FIG. 4 illustrates data demonstrating that that the potent
effects of Eg5 2263 U/U SNALP on cell viability is due to the
silencing of Eg5 protein. Top panel: Eg5:GAPD mRNA ratios, bottom
panel: Percent knockdown of Eg5 mRNA versus non-treated cells.
[0033] FIG. 5 illustrates data demonstrating certain characteristic
changes seen in cell phenotype following treatment with Eg5 O/O
siRNA.
[0034] FIG. 6 illustrates a list showing the sequences of various
2'-OMe modified Eg5 2263 siRNAs (SEQ ID NOS:1-3, 2, 3, 4, 2, 1, 5,
1, 6, 3, 5, 3, 6, 4, 6, 4 and 5, respectively).
[0035] FIG. 7 illustrates data demonstrating the activity of 2'-OMe
modified Eg5 2263 siRNAs in HeLa cells (human).
[0036] FIG. 8 illustrates data demonstrating the activity of 2'-OMe
modified Eg5 2263 siRNAs in Neuro2A cells (mouse).
[0037] FIG. 9 illustrates data demonstrating the Interferon
induction activity for various 2'-OMe modified Eg5 2263 siRNAs,
(i.e., U/O, G/O, U/U, G/G) in a SNALP formulation.
[0038] FIG. 10 illustrates data demonstrating the antibody response
against the delivery vehicle for 2'-OMe modified Eg5 2663 U/U SNALP
as compared to an unmodified Eg5 siRNA.
[0039] FIG. 11 illustrates data demonstrating the RNAi activity of
2'-OMe modified Eg5 2263 U/U SNALP against a range of tumor
cells.
[0040] FIG. 12 illustrates data demonstrating the induction of
apoptosis by Eg5 2263 U/U SNALP in human hepatocellular carcinoma
cells.
[0041] FIG. 13 illustrates data demonstrating the induction of
apoptosis by Eg5 2263 U/U SNALP in human colorectal cancer
cells.
[0042] FIG. 14 illustrates data comparing the induction of
apoptosis by Eg5 2263 U/U SNALP with a small molecule Eg5 inhibitor
in human colorectal cells.
[0043] FIG. 15 illustrates data comparing the RNAi activity of Eg5
2263 U/U SNALP vs. a small molecule Eg5 inhibitor in a variety of
cancer cells.
[0044] FIG. 16 illustrates data demonstrating the stability of
naked Eg5 siRNA and SNALP encapsulated Eg5 O/O siRNA toward serum
nuclease degradation.
[0045] FIG. 17 illustrates data demonstrating in vivo s.c. tumor
growth of Neuro2A after treatment with Eg5 2263 U/U SNALP.
[0046] FIG. 18 illustrates data demonstrating that in vivo dosing
with Eg5 2263 U/U SNALP in mice bearing s.c. Neuro2A tumors is well
tolerated.
[0047] FIG. 19 illustrates data showing that the tumor
histopathology of the intrahepatic Neuro2A tumor that was treated
with Eg5 2263 U/U SNALP.
[0048] FIG. 20 illustrates data showing the tumor histopathology of
the intrahepatic Neuro2A tumor that was treated with control
SNALP
[0049] FIG. 21 is Table 1 which sets forth a list of Eg5 siRNA (SEQ
ID NOS:7-32).
[0050] FIG. 22 is Table 2 which sets forth an additional list of
Eg5 siRNA (SEQ ID NOS:33-62).
[0051] FIG. 23 is Table 3 which sets forth a list of EGFR siRNA
(SEQ ID NOS:63-92).
[0052] FIG. 24 is Table 4 which sets forth an additional list of
EGFR siRNA (SEQ ID NOS:93-118).
[0053] FIG. 25 is Table 5 which sets forth a list of XIAP siRNA
(SEQ ID NOS:119-145).
[0054] FIG. 26 is Table 6 which sets forth an additional list of
XIAP siRNA (SEQ ID NOS:146-173).
[0055] FIG. 27 is Table 7 which sets forth an additional list of
Eg5 siRNA (SEQ ID NOS:174-4977).
[0056] FIG. 28 is Table 8 which sets forth an additional list of
EGFR siRNA (SEQ ID NOS:4978-10362).
[0057] FIG. 29 is Table 9 which sets forth an additional list of
XIAP siRNA (SEQ ID NOS:10363-18497).
[0058] FIG. 30 illustrates data showing in vitro silencing of EGFR
mRNA by the panels of EGFR siRNA sequences set forth in Tables 3
and 4.
[0059] FIG. 31 illustrates data showing the silencing of EGFR mRNA
correlates with a decrease in tumor cell viability.
[0060] FIG. 32 illustrates data showing in vitro silencing of EGFR
mRNA by EGFR SNALP.
[0061] FIG. 33 illustrates data showing in vitro silencing of XIAP
mRNA by XIAP SNALP.
[0062] FIG. 34 illustrates data showing the cells treated with XIAP
SNALP are sensitized to Eg5 inhibitors.
[0063] FIG. 35 illustrates data showing that silencing of XAIP mRNA
with XIAP SNALP sensitizes tumor cells to killing by Eg5 SNALP.
DETAILED DESCRIPTION OF THE INVENTION
I. Introduction
[0064] The invention provides compositions and methods for treating
cancer. In particular, the invention provides nucleic acid-lipid
particles comprising siRNA molecules that silence genes expressed
in cancer including, e.g., growth factors (e.g. epidermal growth
factor ("EGF") and insulin growth factor-1 ("IGF-1")), growth
factor receptors (e.g., epidermal growth factor receptor ("EGFR")
and hepatocyte growth factor receptor (i.e. c-Met)), mitotic
spindle proteins (e.g., kinesins such as kinesin family member 11
("Eg5" or "KIF11"), anti-apoptotic molecules (e.g., caspase
inhibitors such as XIAP and CrmA, survivin, bcl-2), cell cycle
proteins (e.g., cyclin E and aurora kinase), angiogenic factors
(e.g., vascular endothelial growth factor ("VEGF") and vascular
endothelial growth factor receptor ("VEGFR")); oncogenes (e.g.,
src, fyn, ras and myc), intracellular signal transducers (e.g.,
mammalian target of rapamycin ("mTOR"), MAP kinase kinases ("MEK")
and nuclear factor kappa-B ("NFkB")), and molecular chaperones
(e.g., HSP90). The lipid portion of the nucleic acid-lipid
particles comprise a cationic lipid, a non-cationic lipid,
optionally a lipid that prevents aggregation of particles. It is a
discovery of the invention that the nucleic acid-lipid particles
described herein are particularly effective for encapsulating and
delivering siRNA molecules that target cancer cells.
[0065] This invention is based in part on the discovery that
silencing Eg5, EGFR and/or XIAP gene expression is an effective
means to halt proliferation of rapidly dividing cells, e.g., cancer
cells. Accordingly, the present invention also provides nucleic
acid-lipid particles that target Eg5, EGFR and/or XIAP gene
expression comprising an siRNA that silences Eg5, EGFR and/or XIAP
gene expression; a cationic lipid; a non-cationic lipid; and a
conjugated lipid that inhibits aggregation of particles. The
invention further provides methods of silencing Eg5, EGFR or XIAP
gene expression by administering the nucleic acid-lipid particles
described herein to a mammalian subject. In addition, the invention
provides methods of treating a subject who suffers from a cell
proliferative disorder, e.g., cancer, by administering the nucleic
acid-lipid particles described herein.
II. Definitions
[0066] The term "Eg5" refers to the kif11 gene product, a member in
a class of kinesin-related proteins that are involved in functions
related to movements of organelles, microtubules, or chromosomes
along microtubules. These functions include axonal transport,
microtubule sliding during nuclear fusion or division, and
chromosome disjunction during meiosis and early mitosis. Eg5
appears to play a critical role in mitosis of mammalian cells.
Sequences for Eg5 are set forth in, e.g., Genbank Accession Nos.
NM.sub.--004523 (human) and NM.sub.--010615 (mouse).
[0067] The term "EGFR" refers to the cell surface receptor,
epidermal growth factor receptor, also known as ERBB1, that is a
member of the ERBB tyrosine kinase family. EGF has 3 regions: one
projects outside the cell and contains the site for binding
epidermal growth factor (EGF) and related growth factors; the
second is embedded in the membrane; the third projects into the
cytoplasm of the cell's interior. EGFR is a phosphotyrosinekinase.
Binding of EGFR by EGF has a profound effect on the differentiation
of specific cells in vivo and is a potent mitogenic factor for a
variety of cultured cells of both ectodermal and mesodermal origin.
Sequences for the EGF gene are set forth in Genbank Accession Nos.
NM.sub.--005228 (human) and NM.sub.--207655 (mouse).
[0068] The term "XIAP" or "X-linked inhibitor of apoptosis" is a
potent member of the inhibitor of apoptosis (IAP) family. All
members of this family possess baculoviral IAP (BIR) repeats,
cysteine-rich domains of approximately 80 amino acids that bind and
inhibit caspases. XIAP has 3 BIR domains and a C-terminal RING zinc
finger that possesses E3 ubiquitin ligase activity. The anticaspase
activity of XIAP and is important in mediating apoptosis resistance
in cancer cells. Sequences for XIAP are set forth in Genbank
Accession Nos. NM.sub.--001167 (human) and NM.sub.--009688
(mouse).
[0069] The term "interfering RNA" or "RNAi" or "interfering RNA
sequence" refers to double-stranded RNA (i.e., duplex RNA) that
targets (i.e., silences, reduces, or inhibits) expression of a
target gene (i.e., by mediating the degradation of mRNAs which are
complementary to the sequence of the interfering RNA) when the
interfering RNA is in the same cell as the target gene. Interfering
RNA thus refers to the double stranded RNA formed by two
complementary strands or by a single, self-complementary strand.
Interfering RNA typically has substantial or complete identity to
the target gene. The sequence of the interfering RNA can correspond
to the full length target gene, or a subsequence thereof.
Interfering RNA includes small-interfering RNA" or "siRNA," i.e.,
interfering RNA of about 15-60, 15-50, 15-50, or 15-40 (duplex)
nucleotides in length, more typically about, 15-30, 15-25 or 19-25
(duplex) nucleotides in length, and is preferably about 20-24 or
about 21-22 or 21-23 (duplex) nucleotides in length (e.g., each
complementary sequence of the double stranded siRNA is 15-60,
15-50, 15-50, 15-40, 15-30, 15-25 or 19-25 nucleotides in length,
preferably about 20-24 or about 21-22 or 21-23 nucleotides in
length, and the double stranded siRNA is about 15-60, 15-50, 15-50,
15-40, 15-30, 15-25 or 19-25 preferably about 20-24 or about 21-22
or 21-23 base pairs in length). siRNA duplexes may comprise 3'
overhangs of about 1 to about 4 nucleotides, preferably of about 2
to about 3 nucleotides and 5' phosphate termini. The siRNA can be
chemically synthesized or maybe encoded by a plasmid (e.g.,
transcribed as sequences that automatically fold into duplexes with
hairpin loops). siRNA can also be generated by cleavage of longer
dsRNA (e.g., dsRNA greater than about 25 nucleotides in length)
with the E coli RNase III or Dicer. These enzymes process the dsRNA
into biologically active siRNA (see, e.g., Yang et al., PNAS USA
99: 9942-7 (2002); Calegari et al., PNAS USA 99: 14236 (2002);
Byrom et al., Ambion TechNotes 10(1): 4-6 (2003); Kawasaki et al.,
Nucleic Acids Res. 31: 981-7 (2003); Knight and Bass, Science 293:
2269-71 (2001); and Robertson et al., J. Biol. Chem. 243: 82
(1968)). Preferably, dsRNA are at least 50 nucleotides to about
100, 200, 300, 400 or 500 nucleotides in length. A dsRNA may be as
long as 1000, 1500, 2000, 5000 nucleotides in length, or longer.
The dsRNA can encode for an entire gene transcript or a partial
gene transcript.
[0070] "Substantial identity" refers to a sequence that hybridizes
to a reference sequence under stringent conditions, or to a
sequence that has a specified percent identity over a specified
region of a reference sequence.
[0071] The phrase "stringent hybridization conditions" refers to
conditions under which a probe will hybridize to its target
subsequence, typically in a complex mixture of nucleic acids, but
to no other sequences. Stringent conditions are sequence-dependent
and will be different in different circumstances. Longer sequences
hybridize specifically at higher temperatures. An extensive guide
to the hybridization of nucleic acids is found in Tijssen,
Techniques in Biochemistry and Molecular Biology--Hybridization
with Nucleic Probes, "Overview of principles of hybridization and
the strategy of nucleic acid assays" (1993). Generally, stringent
conditions are selected to be about 5-10.degree. C. lower than the
thermal melting point (T.sub.m) for the specific sequence at a
defined ionic strength pH. The T.sub.m is the temperature (under
defined ionic strength, pH, and nucleic concentration) at which 50%
of the probes complementary to the target hybridize to the target
sequence at equilibrium (as the target sequences are present in
excess, at T.sub.m, 50% of the probes are occupied at equilibrium).
Stringent conditions may also be achieved with the addition of
destabilizing agents such as formamide. For selective or specific
hybridization, a positive signal is at least two times background,
preferably 10 times background hybridization.
[0072] Exemplary stringent hybridization conditions can be as
following: 50% formamide, 5.times.SSC, and 1% SDS, incubating at
42.degree. C., or, 5.times.SSC, 1% SDS, incubating at 65.degree.
C., with wash in 0.2.times.SSC, and 0.1% SDS at 65.degree. C. For
PCR, a temperature of about 36.degree. C. is typical for low
stringency amplification, although annealing temperatures may vary
between about 32.degree. C. and 48.degree. C. depending on primer
length. For high stringency PCR amplification, a temperature of
about 62.degree. C. is typical, although high stringency annealing
temperatures can range from about 50.degree. C. to about 65.degree.
C., depending on the primer length and specificity. Typical cycle
conditions for both high and low stringency amplifications include
a denaturation phase of 90.degree. C.-95.degree. C. for 30 sec-2
min., an annealing phase lasting 30 sec.-2 min., and an extension
phase of about 72.degree. C. for 1-2 min. Protocols and guidelines
for low and high stringency amplification reactions are provided,
e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and
Applications, Academic Press, Inc. N.Y.).
[0073] Nucleic acids that do not hybridize to each other under
stringent conditions are still substantially identical if the
polypeptides which they encode are substantially identical. This
occurs, for example, when a copy of a nucleic acid is created using
the maximum codon degeneracy permitted by the genetic code. In such
cases, the nucleic acids typically hybridize under moderately
stringent hybridization conditions. Exemplary "moderately stringent
hybridization conditions" include a hybridization in a buffer of
40% formamide, 1 M NaCl, 1% SDS at 37.degree. C., and a wash in
1.times.SSC at 45.degree. C. A positive hybridization is at least
twice background. Those of ordinary skill will readily recognize
that alternative hybridization and wash conditions can be utilized
to provide conditions of similar stringency. Additional guidelines
for determining hybridization parameters are provided in numerous
reference, e.g., and Current Protocols in Molecular Biology, ed.
Ausubel, et al.
[0074] The terms "substantially identical" or "substantial
identity," in the context of two or more nucleic acids, refer to
two or more sequences or subsequences that are the same or have a
specified percentage of nucleotides that are the same (i.e., at
least about 60%, preferably 65%, 70%, 75%, preferably 80%, 85%,
90%, or 95% identity over a specified region), when compared and
aligned for maximum correspondence over a comparison window, or
designated region as measured using one of the following sequence
comparison algorithms or by manual alignment and visual inspection.
This definition, when the context indicates, also refers
analogously to the complement of a sequence. Preferably, the
substantial identity exists over a region that is at least about 5,
10, 15, 20, 25, 30, 35, 40, 45, 50, 75, or 100 nucleotides in
length.
[0075] For sequence comparison, typically one sequence acts as a
reference sequence, to which test sequences are compared. When
using a sequence comparison algorithm, test and reference sequences
are entered into a computer, subsequence coordinates are
designated, if necessary, and sequence algorithm program parameters
are designated. Default program parameters can be used, or
alternative parameters can be designated. The sequence comparison
algorithm then calculates the percent sequence identities for the
test sequences relative to the reference sequence, based on the
program parameters.
[0076] A "comparison window", as used herein, includes reference to
a segment of any one of the number of contiguous positions selected
from the group consisting of from 20 to 600, usually about 50 to
about 200, more usually about 100 to about 150 in which a sequence
may be compared to a reference sequence of the same number of
contiguous positions after the two sequences are optimally aligned.
Methods of alignment of sequences for comparison are well-known in
the art. Optimal alignment of sequences for comparison can be
conducted, e.g., by the local homology algorithm of Smith &
Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment
algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970),
by the search for similarity method of Pearson & Lipman, Proc.
Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized
implementations of these algorithms (GAP, BESTFIT, FASTA, and
TFASTA in the Wisconsin Genetics Software Package, Genetics
Computer Group, 575 Science Dr., Madison, Wis.), or by manual
alignment and visual inspection (see, e.g., Current Protocols in
Molecular Biology (Ausubel et al., eds. 1995 supplement)).
[0077] A preferred example of algorithm that is suitable for
determining percent sequence identity and sequence similarity are
the BLAST and BLAST 2.0 algorithms, which are described in Altschul
et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J.
Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0
are used, with the parameters described herein, to determine
percent sequence identity for the nucleic acids and proteins of the
invention. Software for performing BLAST analyses is publicly
available through the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/). This algorithm involves first
identifying high scoring sequence pairs (HSPs) by identifying short
words of length W in the query sequence, which either match or
satisfy some positive-valued threshold score T when aligned with a
word of the same length in a database sequence. T is referred to as
the neighborhood word score threshold (Altschul et al., supra).
These initial neighborhood word hits act as seeds for initiating
searches to find longer HSPs containing them. The word hits are
extended in both directions along each sequence for as far as the
cumulative alignment score can be increased. Cumulative scores are
calculated using, for nucleotide sequences, the parameters M
(reward score for a pair of matching residues; always >0) and N
(penalty score for mismatching residues; always <0). For amino
acid sequences, a scoring matrix is used to calculate the
cumulative score. Extension of the word hits in each direction are
halted when: the cumulative alignment score falls off by the
quantity X from its maximum achieved value; the cumulative score
goes to zero or below, due to the accumulation of one or more
negative-scoring residue alignments; or the end of either sequence
is reached. The BLAST algorithm parameters W, T, and X determine
the sensitivity and speed of the alignment. The BLASTN program (for
nucleotide sequences) uses as defaults a wordlength (W) of 11, an
expectation (E) or 10, M=5, N=-4 and a comparison of both strands.
For amino acid sequences, the BLASTP program uses as defaults a
wordlength of 3, and expectation (E) of 10, and the BLOSUM62
scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci.
USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10,
M=5, N=-4, and a comparison of both strands.
[0078] The BLAST algorithm also performs a statistical analysis of
the similarity between two sequences (see, e.g., Karlin &
Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One
measure of similarity provided by the BLAST algorithm is the
smallest sum probability (P(N)), which provides an indication of
the probability by which a match between two nucleotide or amino
acid sequences would occur by chance. For example, a nucleic acid
is considered similar to a reference sequence if the smallest sum
probability in a comparison of the test nucleic acid to the
reference nucleic acid is less than about 0.2, more preferably less
than about 0.01, and most preferably less than about 0.001.
[0079] The phrase "inhibiting expression of a target gene" refers
to the ability of a siRNA of the invention to silence, reduce, or
inhibit expression of a target gene (e.g., an Eg5, EGFR or XIAP
gene). To examine the extent of gene silencing, a test sample
(e.g., a biological sample from organism of interest expressing the
target gene or a sample of cells in culture expressing the target
gene) is contacted with an siRNA that silences, reduces, or
inhibits expression of the target gene. Expression of the target
gene in the test sample is compared to expression of the target
gene in a control sample (e.g., a biological sample from organism
of interest expressing the target gene or a sample of cells in
culture expressing the target gene) that is not contacted with the
siRNA. Control samples (i.e., samples expressing the target gene)
are assigned a value of 100%. Silencing, inhibition, or reduction
of expression of a target gene is achieved when the value of the
test sample relative to the control sample is about 95%, 90%, 85%,
80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or
10%. Suitable assays include, e.g., examination of protein or mRNA
levels using techniques known to those of skill in the art such as
dot blots, northern blots, in situ hybridization, ELISA,
immunoprecipitation, enzyme function, as well as phenotypic assays
known to those of skill in the art.
[0080] "Nucleic acid" refers to deoxyribonucleotides or
ribonucleotides and polymers thereof in single- or double-stranded
form. The term encompasses nucleic acids containing known
nucleotide analogs or modified backbone residues or linkages, which
are synthetic, naturally occurring, and non-naturally occurring,
which have similar binding properties as the reference nucleic
acid, and which are metabolized in a manner similar to the
reference nucleotides. Examples of such analogs include, without
limitation, phosphorothioates, phosphoramidates, methyl
phosphonates, chiral-methyl phosphonates, 2-O-methyl
ribonucleotides, peptide-nucleic acids (PNAs).
[0081] An "effective amount" or "therapeutically effective amount"
of a siRNA is an amount sufficient to produce the desired effect,
e.g., a decrease in the expression of a target sequence in
comparison to the normal expression level detected in the absence
of the siRNA.
[0082] The term "lipid" refers to a group of organic compounds that
include, but are not limited to, esters of fatty acids and are
characterized by being insoluble in water, but soluble in many
organic solvents. They are usually divided into at least three
classes: (1) "simple lipids` which include fats and oils as well as
waxes; (2) "compound lipids" which include phospholipids and
glycolipids; (3) "derived lipids" such as steroids.
[0083] "Lipid vesicle" refers to any lipid composition that can be
used to deliver a compound including, but not limited to,
liposomes, wherein an aqueous volume is encapsulated by an
amphipathic lipid bilayer; or wherein the lipids coat an interior
comprising a large molecular component, such as a plasmid
comprising an interfering RNA sequence, with a reduced aqueous
interior; or lipid aggregates or micelles, wherein the encapsulated
component is contained within a relatively disordered lipid
mixture.
[0084] As used herein, "lipid encapsulated" can refer to a lipid
formulation that provides a compound with full encapsulation,
partial encapsulation, or both. In some embodiments, the nucleic
acid is fully encapsulated in the lipid formulation (e.g., to form
an SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle).
[0085] As used herein, the term "cell proliferative disorder"
includes disorders involving the undesired proliferation of a cell.
Non-limiting examples of such disorders include neoplasias (i.e.,
cancer), hyperplasias, restenosis, cardiac hypertrophy, immune
disorders and inflammation.
[0086] The nucleic acid-lipid particles of the present invention
typically have a mean diameter of less than about 150 nm and are
substantially nontoxic. In addition, the nucleic acids when present
in the nucleic acid-lipid particles of the present invention are
resistant in aqueous solution to degradation with a nuclease.
Nucleic acid-lipid particles and their method of preparation are
disclosed in U.S. Pat. No. 5,976,567, U.S. Pat. No. 5,981,501 and
PCT Patent Publication No. WO 96/40964.
[0087] Various suitable cationic lipids may be used in the present
invention, either alone or in combination with one or more other
cationic lipid species or non-cationic lipid species.
[0088] The cationic lipids of Formula I and Formula II described
herein typically carry a net positive charge at a selected pH, such
as physiological pH. It has been surprisingly found that cationic
lipids comprising alkyl chains with multiple sites of unsaturation,
e.g., at least two or three sites of unsaturation, are particularly
useful for forming lipid-nucleic acid particles with increased
membrane fluidity. A number of cationic lipids and related analogs,
which are also useful in the present invention, have been described
in U.S. Pat. Nos. 5,208,036, 5,264,618, 5,279,833 and 5,283,185,
and WO 96/10390, the disclosures of which are incorporated herein
by reference.
[0089] The noncationic lipids used in the present invention can be
any of a variety of neutral uncharged, zwitterionic or anionic
lipids capable of producing a stable complex. They are preferably
neutral, although they can alternatively be negatively charged.
Examples of noncationic lipids useful in the present invention
include: phospholipid-related materials, such as lecithin,
phosphatidylethanolamine, lysolecithin,
lysophosphatidylethanolamine, phosphatidylserine,
phosphatidylinositol, sphingomyelin, cephalin, cardiolipin,
phosphatidic acid, cerebrosides, dicetylphosphate,
distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine
(DOPC), dipalmitoylphosphatidylcholine (DPPC),
dioleoylphosphatidylglycerol (DOPG),
dipalmitoylphosphatidylglycerol (DPPG),
dioleoyl-phosphatidylethanolamine (DOPE),
palmitoyloleoylphosphatidylcholine (POPC),
palmitoyloleoyl-phosphatidylethanolamine (POPE) and
dioleoyl-phosphatidylethanolamine
4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal).
Noncationic lipids or sterols such as cholesterol may be present.
Additional nonphosphorous containing lipids are, e.g.,
stearylamine, dodecylamine, hexadecylamine, acetyl palmitate,
glycerolricinoleate, hexadecyl stereate, isopropyl myristate,
amphoteric acrylic polymers, triethanolamine-lauryl sulfate,
alkyl-aryl sulfate polyethyloxylated fatty acid amides,
dioctadecyldimethyl ammonium bromide and the like,
diacylphosphatidylcholine, diacylphosphatidylethanolamine,
ceramide, sphingomyelin, cephalin, and cerebrosides. Other lipids
such as lysophosphatidylcholine and lysophosphatidylethanolamine
may be present. Noncationic lipids also include polyethylene
glycol-based polymers such as PEG 2000, PEG 5000 and polyethylene
glycol conjugated to phospholipids or to ceramides (referred to as
PEG-Cer).
[0090] In preferred embodiments, the noncationic lipids are
diacylphosphatidylcholine (e.g., distearoylphosphatidylcholine,
dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and
dilinoleoylphosphatidylcholine), diacylphosphatidylethanolamine
(e.g., dioleoylphosphatidylethanolamine and
palmitoyloleoylphosphatidylethanolamine), ceramide or
sphingomyelin. The acyl groups in these lipids are preferably acyl
groups derived from fatty acids having C.sub.10-C.sub.24 carbon
chains. More preferably the acyl groups are lauroyl, myristoyl,
palmitoyl, stearoyl or oleoyl. In particularly preferred
embodiments, the noncationic lipid will be cholesterol,
1,2-sn-dioleoylphosphatidylethanolamine, or egg sphingomyelin
(ESM).
[0091] In addition to cationic and non-cationic lipids, the nucleic
acid-lipid particles (e.g., SPLPs and SNALPs of the present
invention comprise bilayer stabilizing component (BSC) such as an
ATTA-lipid or a PEG-lipid, such as PEG coupled to dialkyloxypropyls
(PEG-DAA) (see, copending U.S. Patent Application No. 60/503,239),
PEG coupled to diacylglycerol (PEG-DAG) (see, copending U.S. patent
application Ser. No. 10/136,707), PEG coupled to
phosphatidylethanolamine (PE) (PEG-PE), or PEG conjugated to
ceramides, or a mixture thereof (see, U.S. Pat. No. 5,885,613,
which is incorporated herein by reference). In one preferred
embodiment, the BSC is a conjugated lipid that inhibits aggregation
of the nucleic acid-lipid particles. Suitable conjugated lipids
include, but are not limited to PEG-lipid conjugates, ATTA-lipid
conjugates, cationic-polymer-lipid conjugates (CPLs) or mixtures
thereof. In one preferred embodiment, the nucleic acid-lipid
particles comprise either a PEG-lipid conjugate or an ATTA-lipid
conjugate together with a CPL.
[0092] PEG is a polyethylene glycol, a linear, water-soluble
polymer of ethylene PEG repeating units with two terminal hydroxyl
groups. PEGs are classified by their molecular weights; for
example, PEG 2000 has an average molecular weight of about 2,000
daltons, and PEG 5000 has an average molecular weight of about
5,000 daltons. PEGs are commercially available from Sigma Chemical
Co. and other companies and include, for example, the following:
monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene
glycol-succinate (MePEG-S), monomethoxypolyethylene
glycol-succinimidyl succinate (MePEG-S--NHS),
monomethoxypolyethylene glycol-amine (MePEG-NH.sub.2),
monomethoxypolyethylene glycol-tresylate (MePEG-TRES), and
monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG-IM). In
addition, monomethoxypolyethyleneglycol-acetic acid
(MePEG-CH.sub.2COOH), is particularly useful for preparing the
PEG-lipid conjugates including, e.g., PEG-DAA conjugates.
[0093] In some embodiments, the PEG has an average molecular weight
of from about 1000 to about 5000 daltons, more preferably, from
about 1,000 to about 3,000 daltons and, even more preferably, of
about 2,000 daltons. The PEG can be optionally substituted by an
alkyl, alkoxy, acyl or aryl group. PEG can be conjugated directly
to the lipid or may be linked to the lipid via a linker moiety. Any
linker moiety suitable for coupling the PEG to a lipid can be used
including, e.g., non-ester containing linker moieties and
ester-containing linker moieties.
[0094] As used herein, the term "non-ester containing linker
moiety" refers to a linker moiety that does not contain a
carboxylic ester bond (--OC(O)--). Suitable non-ester containing
linker moieties include, but are not limited to, amido
(--C(O)NH--), amino (--NR--), carbonyl (--C(O)--), carbamate
(--NHC(O)O--), urea (--NHC(O)NH--), disulphide (--S--S--), ether
(--O--), succinyl (--(O)CCH.sub.2CH.sub.2C(O)--), succinamidyl
(--NHC(O)CH.sub.2CH.sub.2C(O)NH--), ether, disulphide, etc. as well
as combinations thereof (such as a linker containing both a
carbamate linker moiety and an amido linker moiety). In some
embodiments, a carbamate linker is used to couple the PEG to the
lipid.
[0095] In other embodiments, an ester containing linker moiety is
used to couple the PEG to the lipid. Suitable ester containing
linker moieties include, e.g., carbonate (--OC(O)O--), succinoyl,
phosphate esters (--O--(O)POH--O--), sulfonate esters, and
combinations thereof.
[0096] As used herein, the term "SNALP" refers to a stable nucleic
acid-lipid particle, including SPLP. A SNALP represents a vesicle
of lipids coating a reduced aqueous interior comprising a nucleic
acid (e.g., ssDNA, dsDNA, ssRNA, dsRNA, siRNA, or a plasmid,
including plasmids from which an interfering RNA is transcribed).
As used herein, the term "SPLP" refers to a nucleic acid-lipid
particle comprising a nucleic acid (e.g., a plasmid) encapsulated
within a lipid vesicle. SNALPs and SPLPs typically contain a
cationic lipid, a non-cationic lipid, and a lipid that prevents
aggregation of the particle (e.g., a PEG-lipid conjugate). SNALPs
and SPLPs have systemic application as they exhibit extended
circulation lifetimes following intravenous (i.v.) injection,
accumulate at distal sites (e.g., sites physically separated from
the administration site) and can mediate gene silencing or gene
expression of a transfected nucleic acid at these distal sites.
SPLPs include "pSPLP" which comprise an encapsulated condensing
agent-nucleic acid complex as set forth in WO 00/03683.
[0097] The term "vesicle-forming lipid" is intended to include any
amphipathic lipid having a hydrophobic moiety and a polar head
group, and which by itself can form spontaneously into bilayer
vesicles in water, as exemplified by most phospholipids.
[0098] The term "vesicle-adopting lipid" is intended to include any
amphipathic lipid that is stably incorporated into lipid bilayers
in combination with other amphipathic lipids, with its hydrophobic
moiety in contact with the interior, hydrophobic region of the
bilayer membrane, and its polar head group moiety oriented toward
the exterior, polar surface of the membrane. Vesicle-adopting
lipids include lipids that on their own tend to adopt a nonlamellar
phase, yet which are capable of assuming a bilayer structure in the
presence of a bilayer-stabilizing component. A typical example is
DOPE (dioleoylphosphatidylethanolamine). Bilayer stabilizing
components include, but are not limited to, conjugated lipids that
inhibit aggregation of the SNALPs, polyamide oligomers (e.g.,
ATTA-lipid derivatives), peptides, proteins, detergents,
lipid-derivatives, PEG-lipid derivatives such as PEG coupled to
dialkyloxypropyls, PEG coupled to diacylglycerols, PEG coupled to
phosphatidyl-ethanolamines, and PEG conjugated to ceramides (see,
U.S. Pat. No. 5,885,613, which is incorporated herein by
reference).
[0099] The term "amphipathic lipid" refers, in part, to any
suitable material wherein the hydrophobic portion of the lipid
material orients into a hydrophobic phase, while the hydrophilic
portion orients toward the aqueous phase. Amphipathic lipids are
usually the major component of a lipid vesicle. Hydrophilic
characteristics derive from the presence of polar or charged groups
such as carbohydrates, phosphate, carboxylic, sulfato, amino,
sulfhydryl, nitro, hydroxy and other like groups. Hydrophobicity
can be conferred by the inclusion of apolar groups that include,
but are not limited to, long chain saturated and unsaturated
aliphatic hydrocarbon groups and such groups substituted by one or
more aromatic, cycloaliphatic or heterocyclic group(s). Examples of
amphipathic compounds include, but are not limited to,
phospholipids, aminolipids and sphingolipids. Representative
examples of phospholipids include, but are not limited to,
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,
phosphatidylinositol, phosphatidic acid, palmitoyloleoyl
phosphatidylcholine, lysophosphatidylcholine,
lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine,
dioleoylphosphatidylcholine, distearoylphosphatidylcholine or
dilinoleoylphosphatidylcholine. Other compounds lacking in
phosphorus, such as sphingolipid, glycosphingolipid families,
diacylglycerols and .beta.-acyloxyacids, are also within the group
designated as amphipathic lipids. Additionally, the amphipathic
lipid described above can be mixed with other lipids including
triglycerides and sterols.
[0100] The term "neutral lipid" refers to any of a number of lipid
species that exist either in an uncharged or neutral zwitterionic
form at a selected pH. At physiological pH, such lipids include,
for example, diacylphosphatidylcholine,
diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin,
cholesterol, cerebrosides and diacylglycerols.
[0101] The term "noncationic lipid" refers to any neutral lipid as
described above as well as anionic lipids.
[0102] The term "anionic lipid" refers to any lipid that is
negatively charged at physiological pH. These lipids include, but
are not limited to, phosphatidylglycerol, cardiolipin,
diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoyl
phosphatidylethanolamines, N-succinyl phosphatidylethanolamines,
N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols,
palmitoyloleyolphosphatidylglycerol (POPG), and other anionic
modifying groups joined to neutral lipids.
[0103] The term "cationic lipid" refers to any of a number of lipid
species that carry a net positive charge at a selected pH, such as
physiological pH (e.g., pH of about 7.0). As used herein,
physiological pH refers to the pH of a biological fluid such as
blood or lymph as well as the pH of a cellular compartment such as
an endosome, an acidic endosome, or a lysosome). Such lipids
include, but are not limited to, N,N-dioleyl-N,N-dimethylammonium
chloride ("DODAC");
N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride
("DOTMA"); N,N-distearyl-N,N-dimethylammonium bromide ("DDAB");
N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
("DOTAP"); 3-(N--(N',N'-dimethylaminoethane)-carbamoyl)cholesterol
("DC-Chol");
N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium
bromide ("DMRIE"); 1,2-DiLinoleyloxy-N,N-dimethylaminopropane
(DLinDMA); and 1,2-Dilinolenyloxy-N,N-dimethylaminopropane
(DLenDMA). The following lipids are cationic and have a positive
charge at below physiological pH or at physiological pH: DODAP,
DODMA, DLinDMA and the like.
[0104] The term "hydrophobic lipid" refers to compounds having
apolar groups that include, but are not limited to, long chain
saturated and unsaturated aliphatic hydrocarbon groups and such
groups optionally substituted by one or more aromatic,
cycloaliphatic or heterocyclic group(s). Suitable examples include,
but are not limited to, diacylglycerol, dialkylglycerol,
N--N-dialkylamino, 1,2-diacyloxy-3-aminopropane and
1,2-dialkyl-3-aminopropane.
[0105] The term "fusogenic" refers to the ability of a liposome, an
SNALP or other drug delivery system to fuse with membranes of a
cell. The membranes can be either the plasma membrane or membranes
surrounding organelles, e.g., endosome, nucleus, etc.
[0106] The term "diacylglycerol" refers to a compound having
2-fatty acyl chains, R.sup.1 and R.sup.2, both of which have
independently between 2 and 30 carbons bonded to the 1- and
2-position of glycerol by ester linkages. The acyl groups can be
saturated or have varying degrees of unsaturation. Diacylglycerols
have the following general formula:
##STR00001##
[0107] The term "dialkyloxypropyl" refers to a compound having
2-alkyl chains, R.sup.1 and R.sup.2, both of which have
independently between 2 and 30 carbons. The alkyl groups can be
saturated or have varying degrees of unsaturation.
Dialkyloxypropyls have the following general formula:
##STR00002##
[0108] The term "ATTA" or "polyamide" refers to, but is not limited
to, compounds disclosed in U.S. Pat. Nos. 6,320,017 and 6,586,559,
both of which are incorporated herein by reference. These compounds
include a compound having the formula
##STR00003##
wherein: R is a member selected from the group consisting of
hydrogen, alkyl and acyl; R.sup.1 is a member selected from the
group consisting of hydrogen and alkyl; or optionally, R and
R.sup.1 and the nitrogen to which they are bound form an azido
moiety; R.sup.2 is a member of the group selected from hydrogen,
optionally substituted alkyl, optionally substituted aryl and a
side chain of an amino acid; R.sup.3 is a member selected from the
group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto,
hydrazino, amino and NR.sup.4R.sup.5, wherein R.sup.4 and R.sup.5
are independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p
is 1 to 4; and q is 0 or 1. It will be apparent to those of skill
in the art that other polyamides can be used in the compounds of
the present invention.
[0109] The term "nucleic acid" or "polynucleotide" refers to a
polymer containing at least two ribonucleotides (e.g. deoxy or
ribo) in either single- or double-stranded form. Unless
specifically limited, the terms encompasses nucleic acids
containing known analogues of natural nucleotides that have similar
binding properties as the reference nucleic acid and are
metabolized in a manner similar to naturally occurring nucleotides.
Unless otherwise indicated, a particular nucleic acid sequence also
implicitly encompasses conservatively modified variants thereof
(e.g., degenerate codon substitutions), alleles, orthologs, SNPs,
and complementary sequences as well as the sequence explicitly
indicated. Specifically, degenerate codon substitutions may be
achieved by generating sequences in which the third position of one
or more selected (or all) codons is substituted with mixed-base
and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res.
19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608
(1985); and Cassol et al. (1992); Rossolini et al., Mol. Cell.
Probes 8:91-98 (1994)). "Nucleotides" contain a sugar deoxyribose
(DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides
are linked together through the phosphate groups. "Bases" include
purines and pyrimidines, which further include natural compounds
adenine, thymine, guanine, cytosine, uracil, inosine, and natural
analogs, and synthetic derivatives of purines and pyrimidines,
which include, but are not limited to, modifications which place
new reactive groups such as, but not limited to, amines, alcohols,
thiols, carboxylates, and alkylhalides. DNA may be in the form of
antisense, plasmid DNA, parts of a plasmid DNA, pre-condensed DNA,
product of a polymerase chain reaction (PCR), vectors (P1, PAC,
BAC, YAC, artificial chromosomes), expression cassettes, chimeric
sequences, chromosomal DNA, or derivatives of these groups. The
term nucleic acid is used interchangeably with gene, cDNA, mRNA
encoded by a gene, and an interfering RNA molecule.
[0110] The term "gene" refers to a nucleic acid (e.g., DNA or RNA)
sequence that comprises partial length or entire length coding
sequences necessary for the production of a polypeptide or
precursor (e.g., Eg5, EGFR or XIAP).
[0111] "Gene product," as used herein, refers to a product of a
gene such as an RNA transcript.
[0112] As used herein, the term "aqueous solution" refers to a
composition comprising in whole, or in part, water.
[0113] As used herein, the term "organic lipid solution" refers to
a composition comprising in whole, or in part, an organic solvent
having a lipid.
[0114] "Distal site," as used herein, refers to a physically
separated site, which is not limited to an adjacent capillary bed,
but includes sites broadly distributed throughout an organism.
[0115] "Serum-stable" in relation to nucleic acid-lipid particles
means that the particle is not significantly degraded after
exposure to a serum or nuclease assay that would significantly
degrade free DNA. Suitable assays include, for example, a standard
serum assay or a DNAse assay such as those described in the
Examples below.
[0116] "Fully encapsulated" in relation to nucleic acid-lipid
particles means that the nucleic acid portion of the particle is
serum stable and is not accessible to a fluorescent dye (e.g., such
as RiboGreen.TM.). In contrast to a nucleic acid that forms a
complex with the lipid vehicle (e.g., a liposome or multilammelar
vesicle), a nucleic acid fully encapsulated in the lipid portion of
a particle does not fluoresce in the presence of a fluorescent
dye.
[0117] "Systemic delivery," as used herein, refers to delivery that
leads to a broad biodistribution of a compound within an organism.
Some techniques of administration can lead to the systemic delivery
of certain compounds, but not others. Systemic delivery means that
a useful, preferably therapeutic, amount of a compound is exposed
to most parts of the body. To obtain broad biodistribution
generally requires a blood lifetime such that the compound is not
rapidly degraded or cleared (such as by first pass organs (liver,
lung, etc.) or by rapid, nonspecific cell binding) before reaching
a disease site distal to the site of administration. Systemic
delivery of nucleic acid-lipid particules can be by any means known
in the art including, for example, intravenous, subcutaneous,
intraperitoneal, In some embodiments, systemic delivery of nucleic
acid-lipid particles is by intravenous delivery.
[0118] "Local delivery" as used herein refers to delivery of a
compound directly to a target site within an organism. For example,
a compound can be locally delivered by direct injection into a
disease site such as a tumor or other target site such as a site of
inflammation or a target organ such as the liver, heart, pancreas,
kidney, and the like.
III. Carrier Systems Containing siRNA
[0119] In one aspect, the present invention provides carrier
systems containing the siRNA molecules described herein. In some
embodiments, the carrier system is a lipid-based carrier system
such as a stabilized nucleic acid-lipid particle (e.g., SNALP or
SPLP), cationic lipid or liposome nucleic acid complexes (i.e.,
lipoplexes), a liposome, a micelle, a virosome, or a mixture
thereof. In other embodiments, the carrier system is a
polymer-based carrier system such as a cationic polymer-nucleic
acid complex (i.e., polyplex). In additional embodiments, the
carrier system is a cyclodextrin-based carrier system such as a
cyclodextrin polymer-nucleic acid complex. In further embodiments,
the carrier system is a protein-based carrier system such as a
cationic peptide-nucleic acid complex. Preferably, the carrier
system is a stabilized nucleic acid-lipid particle such as a SNALP
or SPLP. One skilled in the art will appreciate that the siRNA
molecules of the present invention can also be delivered as naked
siRNA.
IV. Stable Nucleic Acid-Lipid Particles (SNALPs) and Properties
Thereof
[0120] The stable nucleic acid-lipid particles or, alternatively,
SNALPs typically comprise an siRNA molecule that targets expression
of a gene expressed in cancer (e.g., an Eg5, EGFR or XIAP gene), a
cationic lipid (e.g., a cationic lipid of Formula I or II), a
noncationic lipid and a bilayer stabilizing component (i.e., a
conjugated lipid that inhibits aggregation of the SNALPs) The
nucleic acid-lipid particles may comprise at least 1, 2, 3, 4, 5,
or more of the sequences set forth in Tables 1-9.
[0121] The SNALPs of the present invention typically have a mean
diameter of about 50 nm to about 150 nm, more typically about 60 nm
to about 130 nm, more typically about 70 nm to about 110 nm, most
typically about 70 to about 90 nm and are substantially nontoxic.
In addition, the nucleic acids present in the SNALPs of the present
invention are resistant in aqueous solution to degradation with a
nuclease.
[0122] In one embodiment, the present invention provides stabilized
nucleic acid-lipid particles (SPLPs or SNALPs) and other
lipid-based carrier systems (e.g., a liposome, a micelle, a
virosome, a lipid-nucleic acid particle, a nucleic acid complex and
mixtures thereof) containing cationic lipids. The lipid-nucleic
acid particles of the present invention typically comprise a
nucleic acid, a cationic lipid, a non-cationic lipid and a
PEG-lipid conjugate. The cationic lipid typically comprises from
about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol
%, from about 10 mol % to about 45 mol %, from about 20 mol % to
about 40 mol %, or from about 30 mol % to about 40 mol % of the
total lipid present in said particle. The non-cationic lipid
typically comprises from about 5 mol % to about 90 mol %, from
about 10 mol % to about 85 mol %, from about 20 mol % to about 80
mol %, from about 30 mol % to about 70 mol %, from about 40 mol %
to about 60 mol % or about 48 mol % of the total lipid present in
said particle. The PEG-lipid conjugate typically comprises from
about 0.5 mol % to about 20 mol %, from about 1.5 mol % to about 18
mol %, from about 4 mol % to about 15 mol %, from about 5 mol % to
about 12 mol %, or about 2 mol % of the total lipid present in said
particle. The nucleic acid-lipid particles of the present invention
may further comprise cholesterol. If present, the cholesterol
typically comprises from about 0 mol % to about 10 mol %, about 2
mol % to about 10 mol %, about 10 mol % to about 60 mol %, from
about 12 mol % to about 58 mol %, from about 20 mol % to about 55
mol %, or about 48 mol % of the total lipid present in said
particle. It will be readily apparent to one of skill in the art
that the proportions of the components of the nucleic acid-lipid
particles may be varied. In a specific formulation, the total lipid
in the nucleic acid-lipid particle comprises 48 mol % cholesterol;
10 mol % DSPC; 2 mol % PEG-cDMA; and 40 mol % DLinDMA of the total
lipid present in said particle.
[0123] A. Cationic Lipids
[0124] Various suitable cationic lipids may be used in the present
invention, either alone or in combination with one or more other
cationic lipid species or neutral lipid species.
[0125] Suitable cationic lipids include, for example, DLinDMA,
DLenDMA, DODAC, DOTMA, DDAB, DOTAP, DOSPA, DOGS, DC-Chol and DMRIE,
or combinations thereof. A number of these lipids and related
analogs, which are also useful in the present invention, have been
described in U.S. Pat. Nos. 5,208,036, 5,264,618, 5,279,833,
5,283,185, 5,753,613 and 5,785,992. Additionally, a number of
commercial preparations of cationic lipids are available and can be
used in the present invention. These include, for example,
LIPOFECTIN.RTM. (commercially available cationic liposomes
comprising DOTMA and DOPE, from GIBCO/BRL, Grand Island, N.Y.,
USA); LIPOFECTAMINE.RTM. (commercially available cationic liposomes
comprising DOSPA and DOPE, from GIBCO/BRL); and TRANSFECTAM.RTM.
(commercially available cationic liposomes comprising DOGS from
Promega Corp., Madison, Wis., USA). In addition, cationic lipids of
Formula I and Formula II can be used in the present invention.
Cationic lipids of Formula I and II have the following
structures:
##STR00004##
wherein R.sup.1 and R.sup.2 are independently selected and are H or
C.sub.1-C.sub.3 alkyls. R.sup.3 and R.sup.4 are independently
selected and are alkyl groups having from about 10 to about 20
carbon atoms; at least one of R.sup.3 and R.sup.4 comprises at
least two sites of unsaturation. In one embodiment, R.sup.3 and
R.sup.4 are both the same, i.e., R.sup.3 and R.sup.4 are both
linoleyl (C18), etc. In another embodiment, R.sup.3 and R.sup.4 are
different, i.e., R.sup.3 is myristyl (C14) and R.sup.4 is linoleyl
(C18). In some embodiments, the cationic lipids of the present
invention are symmetrical, i.e., R.sup.3 and R.sup.4 are both the
same. In another preferred embodiment, both R.sup.3 and R.sup.4
comprise at least two sites of unsaturation. In some embodiments,
R.sup.3 and R.sup.4 are independently selected from dodecadienyl,
tetradecadienyl, hexadecadienyl, linoleyl, and icosadienyl. In some
embodiments, R.sup.3 and R.sup.4 are both linoleyl. In some
embodiments, R.sup.3 and R.sup.4 comprise at least three sites of
unsaturation and are independently selected from, e.g.,
dodecatrienyl, tetradectrienyl, hexadecatrienyl, linolenyl, and
icosatrienyl.
[0126] The cationic lipids of Formula I and Formula II described
herein typically carry a net positive charge at a selected pH, such
as physiological pH. It has been surprisingly found that cationic
lipids comprising alkyl chains with multiple sites of unsaturation,
e.g., at least two or three sites of unsaturation, are particularly
useful for forming lipid-nucleic acid particles with increased
membrane fluidity. A number of cationic lipids and related analogs,
which are also useful in the present invention, have been described
in U.S. Pat. Nos. 5,208,036, 5,264,618, 5,279,833 and 5,283,185,
and WO 96/10390.
[0127] Additional suitable cationic lipids include, e.g.,
dioctadecyldimethylammonium ("DODMA"), Distearyldimethylammonium
("DSDMA"), N,N-dioleyl-N,N-dimethylammonium chloride ("DODAC");
N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride
("DOTMA"); N,N-distearyl-N,N-dimethylammonium bromide ("DDAB");
N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
("DOTAP"); 3-(N--(N',N'-dimethylaminoethane)-carbamoyl)cholesterol
("DC-Chol") and
N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium
bromide ("DMRIE"). A number of these lipids and related analogs,
which are also useful in the present invention, have been described
in U.S. Pat. Nos. 5,208,036, 5,264,618, 5,279,833, 5,283,185,
5,753,613 and 5,785,992.
[0128] B. Non-Cationic Lipids
[0129] The noncationic lipids used in the present invention can be
any of a variety of neutral uncharged, zwitterionic or anionic
lipids capable of producing a stable complex. They are preferably
neutral, although they can alternatively be negatively charged.
Examples of noncationic lipids useful in the present invention
include: phospholipid-related materials, such as lecithin,
phosphatidylethanolamine, lysolecithin,
lysophosphatidylethanolamine, phosphatidylserine,
phosphatidylinositol, sphingomyelin, cephalin, cardiolipin,
phosphatidic acid, cerebrosides, dicetylphosphate,
distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine
(DOPC), dipalmitoylphosphatidylcholine (DPPC),
dioleoylphosphatidylglycerol (DOPG),
dipalmitoylphosphatidylglycerol (DPPG),
dioleoyl-phosphatidylethanolamine (DOPE),
palmitoyloleoylphosphatidylcholine (POPC),
palmitoyloleoyl-phosphatidylethanolamine (POPE) and
dioleoyl-phosphatidylethanolamine
4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal),
dipalmitoyl phosphatidyl ethanolamine (DPPE),
dimyristoylphosphoethanolamine (DMPE),
distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE,
16-O-dimethyl PE, 18-1-trans PE,
1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), and
1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE).
Noncationic lipids or sterols such as cholesterol may be present.
Additional nonphosphorous containing lipids are, e.g.,
stearylamine, dodecylamine, hexadecylamine, acetyl palmitate,
glycerolricinoleate, hexadecyl stereate, isopropyl myristate,
amphoteric acrylic polymers, triethanolamine-lauryl sulfate,
alkyl-aryl sulfate polyethyloxylated fatty acid amides,
dioctadecyldimethyl ammonium bromide and the like,
diacylphosphatidylcholine, diacylphosphatidylethanolamine,
ceramide, sphingomyelin, cephalin, and cerebrosides. Other lipids
such as lysophosphatidylcholine and lysophosphatidylethanolamine
may be present. Noncationic lipids also include polyethylene
glycol-based polymers such as PEG 2000, PEG 5000 and polyethylene
glycol conjugated to phospholipids or to ceramides (referred to as
PEG-Cer).
[0130] In preferred embodiments, the noncationic lipids are
diacylphosphatidylcholine (e.g., distearoylphosphatidylcholine,
dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and
dilinoleoylphosphatidylcholine), diacylphosphatidylethanolamine
(e.g., dioleoylphosphatidylethanolamine and
palmitoyloleoylphosphatidylethanolamine), ceramide or
sphingomyelin. The acyl groups in these lipids are preferably acyl
groups derived from fatty acids having C.sub.10-C.sub.24 carbon
chains. More preferably the acyl groups are lauroyl, myristoyl,
palmitoyl, stearoyl or oleoyl. In particularly preferred
embodiments, the noncationic lipid will be cholesterol,
1,2-sn-dioleoylphosphatidylethanolamine, or egg sphingomyelin
(ESM).
[0131] C. Bilayer Stabilizing Component
[0132] In addition to cationic and non-cationic lipids, the nucleic
acid-lipid particles (e.g., SNALPs and SPLPs) of the present
invention comprise bilayer stabilizing component (BSC) such as an
ATTA-lipid or a PEG-lipid, such as PEG coupled to dialkyloxypropyls
(PEG-DAA) as described in, e.g., WO 05/026372, PEG coupled to
diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent
Publication Nos. 20030077829 and 2005008689), PEG coupled to
phosphatidylethanolamine (PE) (PEG-PE), or PEG conjugated to
ceramides, or a mixture thereof (see, U.S. Pat. No. 5,885,613). In
one preferred embodiment, the BSC is a conjugated lipid that
inhibits aggregation of the nucleic acid-lipid particles. Suitable
conjugated lipids include, but are not limited to PEG-lipid
conjugates, ATTA-lipid conjugates, cationic-polymer-lipid
conjugates (CPLs) or mixtures thereof. In one preferred embodiment,
the nucleic acid-lipid particles comprise either a PEG-lipid
conjugate or an ATTA-lipid conjugate together with a CPL.
[0133] PEG is a polyethylene glycol, a linear, water-soluble
polymer of ethylene PEG repeating units with two terminal hydroxyl
groups. PEGs are classified by their molecular weights; for
example, PEG 2000 has an average molecular weight of about 2,000
daltons, and PEG 5000 has an average molecular weight of about
5,000 daltons. PEGs are commercially available from Sigma Chemical
Co. and other companies and include, for example, the following:
monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene
glycol-succinate (MePEG-S), monomethoxypolyethylene
glycol-succinimidyl succinate (MePEG-S--NHS),
monomethoxypolyethylene glycol-amine (MePEG-NH.sub.2),
monomethoxypolyethylene glycol-tresylate (MePEG-TRES), and
monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG-IM). In
addition, monomethoxypolyethyleneglycol-acetic acid
(MePEG-CH.sub.2COOH), is particularly useful for preparing the
PEG-lipid conjugates including, e.g., PEG-DAA conjugates.
[0134] In some embodiments, the PEG has an average molecular weight
of from about 550 daltons to about 10,000 daltons, more preferably
of about 750 daltons to about 5,000 daltons, more preferably of
about 1,000 daltons to about 5,000 daltons, more preferably of
about 1,500 daltons to about 3,000 daltons and, even more
preferably, of about 2,000 daltons, or about 750 daltons. The PEG
can be optionally substituted by an alkyl, alkoxy, acyl or aryl
group. PEG can be conjugated directly to the lipid or may be linked
to the lipid via a linker moiety. Any linker moiety suitable for
coupling the PEG to a lipid can be used including, e.g., non-ester
containing linker moieties and ester-containing linker moieties. In
some embodiments, the linker moiety is a non-ester containing
linker moiety. As used herein, the term "non-ester containing
linker moiety" refers to a linker moiety that does not contain a
carboxylic ester bond (--OC(O)--). Suitable non-ester containing
linker moieties include, but are not limited to, amido
(--C(O)NH--), amino (--NR--), carbonyl (--C(O)--), carbamate
(--NHC(O)O--), urea (--NHC(O)NH--), disulphide (--S--S--), ether
(--O--), succinyl (--(O)CCH.sub.2CH.sub.2C(O)--), succinamidyl
(--NHC(O)CH.sub.2CH.sub.2C(O)NH--), ether, disulphide, etc. as well
as combinations thereof (such as a linker containing both a
carbamate linker moiety and an amido linker moiety). In some
embodiments, a carbamate linker is used to couple the PEG to the
lipid.
[0135] In other embodiments, an ester containing linker moiety is
used to couple the PEG to the lipid. Suitable ester containing
linker moieties include, e.g., carbonate (--OC(O)O--), succinoyl,
phosphate esters (--O--(O)POH--O--), sulfonate esters, and
combinations thereof.
[0136] Phosphatidylethanolamines having a variety of acyl chain
groups of varying chain lengths and degrees of saturation can be
conjugated to polyethyleneglycol to form the bilayer stabilizing
component. Such phosphatidylethanolamines are commercially
available, or can be isolated or synthesized using conventional
techniques known to those of skilled in the art.
Phosphatidylethanolamines containing saturated or unsaturated fatty
acids with carbon chain lengths in the range of C.sub.10 to
C.sub.20 are preferred. Phosphatidylethanolamines with mono- or
diunsaturated fatty acids and mixtures of saturated and unsaturated
fatty acids can also be used. Suitable phosphatidylethanolamines
include, but are not limited to, the following:
dimyristoylphosphatidylethanolamine (DMPE),
dipalmitoylphosphatidylethanolamine (DPPE),
dioleoylphosphatidylethanolamine (DOPE) and
distearoylphosphatidylethanolamine (DSPE).
[0137] In some embodiments, the PEG-lipid is a PEG-DAA conjugate
has the following formula:
##STR00005##
[0138] In Formula VI, R.sup.1 and R.sup.2 are independently
selected and are alkyl groups having from about 10 to about 22
carbon atoms. The long-chain alkyl groups can be saturated or
unsaturated. Suitable alkyl groups include, but are not limited to,
lauryl (C12), myristyl (C14), palmityl (C16), stearyl (C18) and
icosyl (C20). In some embodiments, R.sup.1 and R.sup.2 are the
same, i.e., R.sup.1 and R.sup.2 are both myristyl (i.e.,
dimyristyl), R.sup.1 and R.sup.2 are both stearyl (i.e.,
distearyl), etc. In some embodiments, the alkyl groups are
saturated.
[0139] In Formula VI above, "PEG" is a polyethylene glycol having
an average molecular weight ranging of about 550 daltons to about
10,000 daltons, about 750 daltons to about 5,000 daltons, about
1,000 daltons to about 5,000 daltons, about 1,500 daltons to about
3,000 daltons, about 2,000 daltons, or about 750 daltons. The PEG
can be optionally substituted with alkyl, alkoxy, acyl or aryl. In
some embodiments, the terminal hydroxyl group is substituted with a
methoxy or methyl group.
[0140] In Formula VI, above, "L" is a non-ester containing linker
moiety or an ester containing linker moiety. In some embodiments, L
is a non-ester containing linker moiety. Suitable non-ester
containing linkers include, but are not limited to, an amido linker
moiety, an amino linker moiety, a carbonyl linker moiety, a
carbamate linker moiety, a urea linker moiety, an ether linker
moiety, a disulphide linker moiety, a succinamidyl linker moiety
and combinations thereof. In some embodiments, the non-ester
containing linker moiety is a carbamate linker moiety (i.e., a
PEG-C-DAA conjugate), an amido linker moiety (i.e., a PEG-A-DAA
conjugate), or a succinamidyl linker moiety (i.e., a PEG-S-DAA
conjugate).
[0141] The PEG-DAA conjugates are synthesized using standard
techniques and reagents known to those of skill in the art. It will
be recognized that the PEG-DAA conjugates will contain various
amide, amine, ether, thio, carbamate and urea linkages. T hose of
skill in the art will recognize that methods and reagents for
forming these bonds are well known and readily available. See,
e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992), Larock,
COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss,
VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY 5th ed. (Longman
1989). It will also be appreciated that any functional groups
present may require protection and deprotection at different points
in the synthesis of the PEG-DAA conjugates. Those of skill in the
art will recognize that such techniques are well known. See, e.g.,
Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley
1991).
[0142] In some embodiments, the PEG-DAA conjugate is a
dilauryloxypropyl (C12)-PEG conjugate, dimyristyloxypropyl
(C14)-PEG conjugate, a dipalmitoyloxypropyl (C16)-PEG conjugate or
a disteryloxypropyl (C18)-PEG conjugate. Those of skill in the art
will readily appreciate that other dialkyloxypropyls can be used in
the PEG-DAA conjugates of the present invention.
[0143] In addition to the foregoing, it will be readily apparent to
those of skill in the art that other hydrophilic polymers can be
used in place of PEG. Examples of suitable polymers that can be
used in place of PEG include, but are not limited to,
polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline,
polyhydroxypropyl methacrylamide, polymethacrylamide and
polydimethylacrylamide, polylactic acid, polyglycolic acid, and
derivatized celluloses, such as hydroxymethylcellulose or
hydroxyethylcellulose.
[0144] In addition to the foregoing components, the SNALPs and
SPLPs of the present invention can further comprise cationic
poly(ethylene glycol) (PEG) lipids, or CPLs, that have been
designed for insertion into lipid bilayers to impart a positive
charge (see, Chen, et al., Bioconj. Chem. 11:433-437 (2000)).
Suitable SPLPs and SPLP-CPLs for use in the present invention, and
methods of making and using SPLPs and SPLP-CPLs, are disclosed,
e.g., in U.S. Pat. No. 6,852,334 and WO 00/62813. Cationic polymer
lipids (CPLs) useful in the present invention have the following
architectural features: (1) a lipid anchor, such as a hydrophobic
lipid, for incorporating the CPLs into the lipid bilayer; (2) a
hydrophilic spacer, such as a polyethylene glycol, for linking the
lipid anchor to a cationic head group; and (3) a polycationic
moiety, such as a naturally occurring amino acid, to produce a
protonizable cationic head group.
[0145] Suitable CPL include compounds of Formula VII:
A-W--Y (VII)
wherein A, W and Y are as described below.
[0146] With reference to Formula VII, "A" is a lipid moiety such as
an amphipathic lipid, a neutral lipid or a hydrophobic lipid that
acts as a lipid anchor. Suitable lipid examples include
vesicle-forming lipids or vesicle adopting lipids and include, but
are not limited to, diacylglycerolyls, dialkylglycerolyls,
N--N-dialkylaminos, 1,2-diacyloxy-3-aminopropanes and
1,2-dialkyl-3-aminopropanes.
[0147] "W" is a polymer or an oligomer, such as a hydrophilic
polymer or oligomer. Typically, the hydrophilic polymer is a
biocompatable polymer that is nonimmunogenic or possesses low
inherent immunogenicity. Alternatively, the hydrophilic polymer can
be weakly antigenic if used with appropriate adjuvants. Suitable
nonimmunogenic polymers include, but are not limited to, PEG,
polyamides, polylactic acid, polyglycolic acid, polylactic
acid/polyglycolic acid copolymers and combinations thereof. In some
embodiments, the polymer has a molecular weight of about 250 to
about 7000 daltons.
[0148] "Y" is a polycationic moiety. The term polycationic moiety
refers to a compound, derivative, or functional group having a
positive charge, typically at least 2 positive charges at a
selected pH, typically physiological pH. Suitable polycationic
moieties include basic amino acids and their derivatives such as
arginine, asparagine, glutamine, lysine and histidine; spermine;
spermidine; cationic dendrimers; polyamines; polyamine sugars; and
amino polysaccharides. The polycationic moieties can be linear,
such as linear tetralysine, branched or dendrimeric in structure.
Polycationic moieties have between about 2 to about 15 positive
charges, between about 2 to about 12 positive charges, or between
about 2 to about 8 positive charges at selected pH values. The
selection of which polycationic moiety to employ may be determined
by the type of liposome application which is desired.
[0149] The charges on the polycationic moieties can be either
distributed around the entire liposome moiety, or alternatively,
they can be a discrete concentration of charge density in one
particular area of the liposome moiety e.g., a charge spike. If the
charge density is distributed on the liposome, the charge density
can be equally distributed or unequally distributed. All variations
of charge distribution of the polycationic moiety are encompassed
by the present invention.
[0150] The lipid "A," and the nonimmunogenic polymer "W," can be
attached by various methods and preferably, by covalent attachment.
Methods known to those of skill in the art can be used for the
covalent attachment of "A" and "W." Suitable linkages include, but
are not limited to, amide, amine, carboxyl, carbonate, carbamate,
ester and hydrazone linkages. It will be apparent to those skilled
in the art that "A" and "W" must have complementary functional
groups to effectuate the linkage. The reaction of these two groups,
one on the lipid and the other on the polymer, will provide the
desired linkage. For example, when the lipid is a diacylglycerol
and the terminal hydroxyl is activated, for instance with NHS and
DCC, to form an active ester, and is then reacted with a polymer
which contains an amino group, such as with a polyamide (see, U.S.
Pat. Nos. 6,320,017 and 6,586,559), an amide bond will form between
the two groups.
[0151] In certain instances, the polycationic moiety can have a
ligand attached, such as a targeting ligand or a chelating moiety
for complexing calcium. Preferably, after the ligand is attached,
the cationic moiety maintains a positive charge. In certain
instances, the ligand that is attached has a positive charge.
Suitable ligands include, but are not limited to, a compound or
device with a reactive functional group and include lipids,
amphipathic lipids, carrier compounds, bioaffinity compounds,
biomaterials, biopolymers, biomedical devices, analytically
detectable compounds, therapeutically active compounds, enzymes,
peptides, proteins, antibodies, immune stimulators, radiolabels,
fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides,
liposomes, virosomes, micelles, immunoglobulins, functional groups,
other targeting moieties, or toxins.
[0152] D. Nucleic Acid Component
[0153] The nucleic acid component of the present invention
comprises an interfering RNA that silences (e.g., partially or
completely inhibits) expression of a gene of interest (e.g., an
Eg5, EGFR and/or XIAP gene). An interfering RNA can be provided in
several forms. For example an interfering RNA can be provided as
one or more isolated small-interfering RNA (siRNA) duplexes, longer
double-stranded RNA (dsRNA) or as siRNA or dsRNA transcribed from a
transcriptional cassette in a DNA plasmid. The interfering RNA can
be administered alone or in combination with the administration of
conventional agents used to treat the disease or disorder
associated with the gene of interest including, e.g., cancer. Genes
of interest include, but are not limited to, genes associated with
viral infection and survival, genes associated with liver and
kidney diseases and disorders, genes associated with tumorigenesis
and cell transformation, angiogenic genes, immunomodulator genes,
such as those associated with inflammatory and autoimmune
responses, ligand receptor genes, and genes associated with
neurodegenerative disorders.
[0154] E. siRNAs
[0155] The siRNAs of the invention are capable of silencing
expression of a target sequence such as, e.g., Eg5, EGFR or XIAP
mRNA. Suitable siRNA sequences are set forth in, e.g., Tables 1-2
and 7 for Eg5; Tables 3-4 and 9 for EGFR; or Tables 5-6 and 9 for
XIAP. For any of the sequences set forth in the Tables above,
thymines (i.e., T) can substituted with uracil ("U") and uracil can
be substituted with ("T"). In some embodiments, the siRNA are about
15 to 30 nucleotides in length.
[0156] 1. Selecting siRNA Sequences
[0157] Suitable siRNA sequences can be identified using any means
known in the art. Typically, the methods described in Elbashir et
al., Nature, 411:494-498 (2001) and Elbashir et al., EMBO J.,
20:6877-6888 (2001) are combined with rational design rules set
forth in Reynolds et al., Nature Biotech., 22:326-330 (2004).
[0158] Generally, the nucleotide sequence 3' of the AUG start codon
of a transcript from the target gene of interest is scanned for
dinucleotide sequences (e.g., AA, NA, CC, GG, or UU, wherein N=C,
G, or U) (see, e.g., Elbashir et al., EMBO J., 20:6877-6888
(2001)). The nucleotides immediately 3' to the dinucleotide
sequences are identified as potential siRNA sequences (i.e., a
target sequence or a sense strand sequence). Typically, the 19, 21,
23, 25, 27, 29, 31, 33, 35, or more nucleotides immediately 3' to
the dinucleotide sequences are identified as potential siRNA
sequences. In some embodiments, the dinucleotide sequence is an AA
or NA sequence and the 19 nucleotides immediately 3' to the AA or
NA dinucleotide are identified as a potential siRNA sequences.
siRNA sequences are usually spaced at different positions along the
length of the target gene. To further enhance silencing efficiency
of the siRNA sequences, potential siRNA sequences may be analyzed
to identify sites that do not contain regions of homology to other
coding sequences, e.g., in the target cell or organism. For
example, a suitable siRNA sequence of about 21 base pairs typically
will not have more than 16-17 contiguous base pairs of homology to
coding sequences in the target cell or organism. If the siRNA
sequences are to be expressed from an RNA Pol III promoter, siRNA
sequences lacking more than 4 contiguous A's or T's are
selected.
[0159] Once a potential siRNA sequence has been identified, the
sequence can be analyzed using a variety of criteria known in the
art. For example, to enhance their silencing efficiency, the siRNA
sequences may be analyzed by a rational design algorithm to
identify sequences that have one or more of the following features:
(1) G/C content of about 25% to about 60% G/C; (2) at least 3 A/Us
at positions 15-19 of the sense strand; (3) no internal repeats;
(4) an A at position 19 of the sense strand; (5) an A at position 3
of the sense strand; (6) a U at position 10 of the sense strand;
(7) no G/C at position 19 of the sense strand; and (8) no G at
position 13 of the sense strand. siRNA design tools that
incorporate algorithms that assign suitable values of each of these
features and are useful for selection of siRNA can be found at,
e.g., http://boz094.ust.hk/RNAi/siRNA. One of skill in the art will
appreciate that sequences with one or more of the foregoing
characteristics may be selected for further analysis and testing as
potential siRNA sequences.
[0160] Additionally, potential siRNA target sequences with one or
more of the following criteria can often be eliminated as siRNA:
(1) sequences comprising a stretch of 4 or more of the same base in
a row; (2) sequences comprising homopolymers of Gs (i.e., to reduce
possible non-specific effects due to structural characteristics of
these polymers; (3) sequences comprising triple base motifs (e.g.,
GGG, CCC, AAA, or TTT); (4) sequences comprising stretches of 7 or
more G/Cs in a row; and (5) sequences comprising direct repeats of
4 or more bases within the candidates resulting in internal
fold-back structures. However, one of skill in the art will
appreciate that sequences with one or more of the foregoing
characteristics may still be selected for further analysis and
testing as potential siRNA sequences.
[0161] In some embodiments, potential siRNA target sequences may be
further analyzed based on siRNA duplex asymmetry as described in,
e.g., Khvorova et al., Cell, 115:209-216 (2003); and Schwarz et
al., Cell, 115:199-208 (2003). In other embodiments, potential
siRNA target sequences may be further analyzed based on secondary
structure at the mRNA target site as described in, e.g., Luo et
al., Biophys. Res. Commun., 318:303-310 (2004). For example, mRNA
secondary structure can be modeled using the Mfold algorithm
(available at
http://www.bioinfo.rpi.edu/applications/mfold/rna/form1.cgi) to
select siRNA sequences which favor accessibility at the mRNA target
site where less secondary structure in the form of base-pairing and
stem-loops is present.
[0162] Once a potential siRNA sequence has been identified, the
sequence can be analyzed for the presence of any immunostimulatory
properties, e.g., using an in vitro cytokine assay or an in vivo
animal model. Motifs in the sense and/or antisense strand of the
siRNA sequence such as GU-rich motifs (e.g.,
5'-GU-3',5'-UGU-3',5'-GUGU-3',5'-UGUGU-3', etc.) can also provide
an indication of whether the sequence may be immunostimulatory.
Once an siRNA molecule is found to be immunostimulatory, it can
then be modified to decrease its immunostimulatory properties as
described herein. As a non-limiting example, an siRNA sequence can
be contacted with a mammalian responder cell under conditions such
that the cell produces a detectable immune response to determine
whether the siRNA is an immunostimulatory or a
non-immunostimulatory siRNA. The mammalian responder cell may be
from a naive mammal (i.e., a mammal that has not previously been in
contact with the siRNA sequence). The mammalian responder cell may
be, e.g., a peripheral blood mononuclear cell (PBMC), a macrophage,
and the like. The detectable immune response may comprise
production of a cytokine or growth factor such as, e.g.,
TNF-.alpha., IFN-.alpha., IFN-.beta., IFN-.gamma., IL-6, IL-12, or
a combination thereof. An siRNA molecule identified as being
immunostimulatory can then be modified to decrease its
immunostimulatory properties by replacing at least one of the
nucleotides on the sense and/or antisense strand with modified
nucleotides. For example, less than about 30% (e.g., less than
about 30%, 25%, 20%, 15%, 10%, or 5%) of the nucleotides in the
double-stranded region of the siRNA duplex can be replaced with
modified nucleotides such as 2'OMe nucleotides. The modified siRNA
can then be contacted with a mammalian responder cell as described
above to confirm that its immunostimulatory properties have been
reduced or abrogated.
[0163] Suitable in vitro assays for detecting an immune response
include, but are not limited to, the double monoclonal antibody
sandwich immunoassay technique of David et al. (U.S. Pat. No.
4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et
al., in Kirkham and Hunter, eds., Radioimmunoassay Methods, E. and
S. Livingstone, Edinburgh (1970)); the "Western blot" method of
Gordon et al. (U.S. Pat. No. 4,452,901); immunoprecipitation of
labeled ligand (Brown et al., J. Biol. Chem., 255:4980-4983
(1980)); enzyme-linked immunosorbent assays (ELISA) as described,
for example, by Raines et al., J. Biol. Chem., 257:5154-5160
(1982); immunocytochemical techniques, including the use of
fluorochromes (Brooks et al., Clin. Exp. Immunol., 39:477 (1980));
and neutralization of activity (Bowen-Pope et al., Proc. Natl.
Acad. Sci. USA, 81:2396-2400 (1984)). In addition to the
immunoassays described above, a number of other immunoassays are
available, including those described in U.S. Pat. Nos. 3,817,827;
3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074;
and 4,098,876.
[0164] A non-limiting example of an in vivo model for detecting an
immune response includes an in vivo mouse cytokine induction assay
that can be performed as follows: (1) siRNA can be administered by
standard intravenous injection in the lateral tail vein; (2) blood
can be collected by cardiac puncture about 6 hours after
administration and processed as plasma for cytokine analysis; and
(3) cytokines can be quantified using sandwich ELISA kits according
to the manufacturer's instructions (e.g., mouse and human
IFN-.alpha. (PBL Biomedical; Piscataway, N.J.); human IL-6 and
TNF-.alpha. (eBioscience; San Diego, Calif.); and mouse IL-6,
TNF-.alpha., and IFN-.gamma. (BD Biosciences; San Diego,
Calif.)).
[0165] Monoclonal antibodies that specifically bind cytokines and
growth factors are commercially available from multiple sources and
can be generated using methods known in the art (see, e.g., Kohler
and Milstein, Nature, 256: 495-497 (1975); and Harlow and Lane,
ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publication,
New York (1999)). Generation of monoclonal antibodies has been
previously described and can be accomplished by any means known in
the art (see, e.g., Buhring et al. in Hybridoma, Vol. 10, No. 1,
pp. 77-78 (1991)). In some methods, the monoclonal antibody is
labeled (e.g., with any composition detectable by spectroscopic,
photochemical, biochemical, electrical, optical, chemical means,
and the like) to facilitate detection.
[0166] F. Generating siRNA Molecules
[0167] siRNA molecules can be provided in several forms including,
e.g., as one or more isolated small-interfering RNA (siRNA)
duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or
dsRNA transcribed from a transcriptional cassette in a DNA plasmid.
The siRNA sequences may have overhangs (e.g., 3' or 5' overhangs as
described in Elbashir et al., Genes Dev., 15:188 (2001) or Nykanen
et al., Cell, 107:309 (2001)), or may lack overhangs (i.e., have
blunt ends).
[0168] An RNA population can be used to provide long precursor
RNAs, or long precursor RNAs that have substantial or complete
identity to a selected target sequence can be used to make the
siRNA. The RNAs can be isolated from cells or tissue, synthesized,
and/or cloned according to methods well known to those of skill in
the art. The RNA can be a mixed population (obtained from cells or
tissue, transcribed from cDNA, subtracted, selected, etc.), or can
represent a single target sequence. RNA can be naturally occurring
(e.g., isolated from tissue or cell samples), synthesized in vitro
(e.g., using T7 or SP6 polymerase and PCR products or a cloned
cDNA), or chemically synthesized.
[0169] To form a long dsRNA, for synthetic RNAs, the complement is
also transcribed in vitro and hybridized to form a dsRNA. If a
naturally occurring RNA population is used, the RNA complements are
also provided (e.g., to form dsRNA for digestion by E. coli RNAse
III or Dicer), e.g., by transcribing cDNAs corresponding to the RNA
population, or by using RNA polymerases. The precursor RNAs are
then hybridized to form double stranded RNAs for digestion. The
dsRNAs can be directly administered to a subject or can be digested
in vitro prior to administration.
[0170] Alternatively, one or more DNA plasmids encoding one or more
siRNA templates are used to provide siRNA. siRNA can be transcribed
as sequences that automatically fold into duplexes with hairpin
loops from DNA templates in plasmids having RNA polymerase III
transcriptional units, for example, based on the naturally
occurring transcription units for small nuclear RNA U6 or human
RNase P RNA H1 (see, Brummelkamp et al., Science, 296:550 (2002);
Donze et al., Nucleic Acids Res., 30:e46 (2002); Paddison et al.,
Genes Dev., 16:948 (2002); Yu et al., Proc. Natl. Acad. Sci. USA,
99:6047 (2002); Lee et al., Nat. Biotech., 20:500 (2002); Miyagishi
et al., Nat. Biotech., 20:497 (2002); Paul et al., Nat. Biotech.,
20:505 (2002); and Sui et al., Proc. Natl. Acad. Sci. USA, 99:5515
(2002)). Typically, a transcriptional unit or cassette will contain
an RNA transcript promoter sequence, such as an H1-RNA or a U6
promoter, operably linked to a template for transcription of a
desired siRNA sequence and a termination sequence, comprised of 2-3
uridine residues and a polythymidine (T5) sequence (polyadenylation
signal) (Brummelkamp et al., supra). The selected promoter can
provide for constitutive or inducible transcription. Compositions
and methods for DNA-directed transcription of RNA interference
molecules is described in detail in U.S. Pat. No. 6,573,099. The
transcriptional unit is incorporated into a plasmid or DNA vector
from which the interfering RNA is transcribed. Plasmids suitable
for in vivo delivery of genetic material for therapeutic purposes
are described in detail in U.S. Pat. Nos. 5,962,428 and 5,910,488.
The selected plasmid can provide for transient or stable delivery
of a target cell. It will be apparent to those of skill in the art
that plasmids originally designed to express desired gene sequences
can be modified to contain a transcriptional unit cassette for
transcription of siRNA.
[0171] Methods for isolating RNA, synthesizing RNA, hybridizing
nucleic acids, making and screening cDNA libraries, and performing
PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene
25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra),
as are PCR methods (see, U.S. Pat. Nos. 4,683,195 and 4,683,202;
PCR Protocols: A Guide to Methods and Applications (Innis et al.,
eds, 1990)). Expression libraries are also well known to those of
skill in the art. Additional basic texts disclosing the general
methods of use in this invention include Sambrook et al., Molecular
Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene
Transfer and Expression: A Laboratory Manual (1990); and Current
Protocols in Molecular Biology (Ausubel et al., eds., 1994).
[0172] Preferably, siRNA molecules are chemically synthesized. The
single-stranded molecules that comprise the siRNA molecule can be
synthesized using any of a variety of techniques known in the art,
such as those described in Usman et al., J. Am. Chem. Soc.,
109:7845 (1987); Scaringe et al., Nucl. Acids Res., 18:5433 (1990);
Wincott et al., Nucl. Acids Res., 23:2677-2684 (1995); and Wincott
et al., Methods Mol. Bio., 74:59 (1997). The synthesis of the
single-stranded molecules makes use of common nucleic acid
protecting and coupling groups, such as dimethoxytrityl at the
5'-end and phosphoramidites at the 3'-end. As a non-limiting
example, small scale syntheses can be conducted on an Applied
Biosystems synthesizer using a 0.2 .mu.mol scale protocol with a
2.5 min coupling step for 2'-O-methylated nucleotides.
Alternatively, syntheses at the 0.2 mmol scale can be performed on
a 96-well plate synthesizer from Protogene (Palo Alto, Calif.).
However, a larger or smaller scale of synthesis is also within the
scope of the present invention. Suitable reagents for synthesis of
the siRNA single-stranded molecules, methods for RNA deprotection,
and methods for RNA purification are known to those of skill in the
art.
[0173] The siRNA molecules can also be synthesized via a tandem
synthesis technique, wherein both strands are synthesized as a
single continuous fragment or strand separated by a cleavable
linker that is subsequently cleaved to provide separate fragments
or strands that hybridize to form the siRNA duplex. The linker can
be a polynucleotide linker or a non-nucleotide linker. The tandem
synthesis of siRNA can be readily adapted to both
multiwell/multiplate synthesis platforms as well as large scale
synthesis platforms employing batch reactors, synthesis columns,
and the like. Alternatively, the siRNA molecules can be assembled
from two distinct single-stranded molecules, wherein one strand
comprises the sense strand and the other comprises the antisense
strand of the siRNA. For example, each strand can be synthesized
separately and joined together by hybridization or ligation
following synthesis and/or deprotection. In certain other
instances, the siRNA molecules can be synthesized as a single
continuous fragment, where the self-complementary sense and
antisense regions hybridize to form an siRNA duplex having hairpin
secondary structure.
[0174] C. Modifying siRNA Sequences
[0175] In certain aspects, the siRNA molecules of the present
invention comprise a duplex having two strands and at least one
modified nucleotide in the double-stranded region, wherein each
strand is about 15 to about 60 nucleotides in length.
Advantageously, the modified siRNA is less immunostimulatory than a
corresponding unmodified siRNA sequence, but retains the capability
of silencing the expression of a target sequence.
[0176] Examples of modified nucleotides suitable for use in the
present invention include, but are not limited to, ribonucleotides
having a 2'-O-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy,
5-C-methyl, 2'-O-(2-methoxyethyl) (MOE), 4'-thio, 2'-amino, or
2'-C-allyl group. Modified nucleotides having a Northern
conformation such as those described in, e.g., Saenger, Principles
of Nucleic Acid Structure, Springer-Verlag Ed. (1984), are also
suitable for use in the siRNA molecules of the present invention.
Such modified nucleotides include, without limitation, locked
nucleic acid (LNA) nucleotides (e.g., 2'-O,
4'-C-methylene-(D-ribofuranosyl) nucleotides),
2'-O-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl
nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides,
2'-deoxy-2'-chloro (2'Cl) nucleotides, and 2'-azido nucleotides. In
certain instances, the siRNA molecules of the present invention
include one or more G-clamp nucleotides. A G-clamp nucleotide
refers to a modified cytosine analog wherein the modifications
confer the ability to hydrogen bond both Watson-Crick and Hoogsteen
faces of a complementary guanine nucleotide within a duplex (see,
e.g., Lin et al., J. Am. Chem. Soc., 120:8531-8532 (1998)). In
addition, nucleotides having a nucleotide base analog such as, for
example, C-phenyl, C-naphthyl, other aromatic derivatives, inosine,
azole carboxamides, and nitroazole derivatives such as
3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole
(see, e.g., Loakes, Nucl. Acids Res., 29:2437-2447 (2001)) can be
incorporated into the siRNA molecules of the present invention.
[0177] In certain embodiments, the siRNA molecules of the present
invention further comprise one or more chemical modifications such
as terminal cap moieties, phosphate backbone modifications, and the
like. Examples of terminal cap moieties include, without
limitation, inverted deoxy abasic residues, glyceryl modifications,
4',5'-methylene nucleotides, 1-(.beta.-D-erythrofuranosyl)
nucleotides, 4'-thio nucleotides, carbocyclic nucleotides,
1,5-anhydrohexitol nucleotides, L-nucleotides, .alpha.-nucleotides,
modified base nucleotides, threo-pentofuranosyl nucleotides,
acyclic 3',4'-seco nucleotides, acyclic 3,4-dihydroxybutyl
nucleotides, acyclic 3,5-dihydroxypentyl nucleotides,
3'-3'-inverted nucleotide moieties, 3'-3'-inverted abasic moieties,
3'-2'-inverted nucleotide moieties, 3'-2'-inverted abasic moieties,
5'-5'-inverted nucleotide moieties, 5'-5'-inverted abasic moieties,
3'-5'-inverted deoxy abasic moieties, 5'-amino-alkyl phosphate,
1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate,
6-aminohexyl phosphate, 1,2-aminododecyl phosphate, hydroxypropyl
phosphate, 1,4-butanediol phosphate, 3'-phosphoramidate,
5'-phosphoramidate, hexylphosphate, aminohexyl phosphate,
3'-phosphate, 5'-amino, 3'-phosphorothioate, 5'-phosphorothioate,
phosphorodithioate, and bridging or non-bridging methylphosphonate
or 5'-mercapto moieties (see, e.g., U.S. Pat. No. 5,998,203;
Beaucage et al., Tetrahedron 49:1925 (1993)). Non-limiting examples
of phosphate backbone modifications (i.e., resulting in modified
internucleotide linkages) include phosphorothioate,
phosphorodithioate, methylphosphonate, phosphotriester, morpholino,
amidate, carbamate, carboxymethyl, acetamidate, polyamide,
sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and
alkylsilyl substitutions (see, e.g., Hunziker et al., Nucleic Acid
Analogues: Synthesis and Properties, in Modern Synthetic Methods,
VCH, 331-417 (1995); Mesmaeker et al., Novel Backbone Replacements
for Oligonucleotides, in Carbohydrate Modifications in Antisense
Research, ACS, 24-39 (1994)). Such chemical modifications can occur
at the 5'-end and/or 3'-end of the sense strand, antisense strand,
or both strands of the siRNA.
[0178] In some embodiments, the sense and/or antisense strand can
further comprise a 3'-terminal overhang having about 1 to about 4
(e.g., 1, 2, 3, or 4) 2'-deoxy ribonucleotides and/or any
combination of modified and unmodified nucleotides. Additional
examples of modified nucleotides and types of chemical
modifications that can be introduced into the modified siRNA
molecules of the present invention are described, e.g., in UK
Patent No. GB 2,397,818 B and U.S. Patent Publication Nos.
20040192626 and 20050282188.
[0179] The siRNA molecules of the present invention can optionally
comprise one or more non-nucleotides in one or both strands of the
siRNA. As used herein, the term "non-nucleotide" refers to any
group or compound that can be incorporated into a nucleic acid
chain in the place of one or more nucleotide units, including sugar
and/or phosphate substitutions, and allows the remaining bases to
exhibit their activity. The group or compound is abasic in that it
does not contain a commonly recognized nucleotide base such as
adenosine, guanine, cytosine, uracil, or thymine and therefore
lacks a base at the 1'-position.
[0180] In other embodiments, chemical modification of the siRNA
comprises attaching a conjugate to the siRNA molecule. The
conjugate can be attached at the 5'- and/or 3'-end of the sense
and/or antisense strand of the siRNA via a covalent attachment such
as, e.g., a biodegradable linker. The conjugate can also be
attached to the siRNA, e.g., through a carbamate group or other
linking group (see, e.g., U.S. Patent Publication Nos. 20050074771,
20050043219, and 20050158727). In certain instances, the conjugate
is a molecule that facilitates the delivery of the siRNA into a
cell. Examples of conjugate molecules suitable for attachment to
the siRNA of the present invention include, without limitation,
steroids such as cholesterol, glycols such as polyethylene glycol
(PEG), human serum albumin (HSA), fatty acids, carotenoids,
terpenes, bile acids, folates (e.g., folic acid, folate analogs and
derivatives thereof), sugars (e.g., galactose, galactosamine,
N-acetyl galactosamine, glucose, mannose, fructose, fucose, etc.),
phospholipids, peptides, ligands for cellular receptors capable of
mediating cellular uptake, and combinations thereof (see, e.g.,
U.S. Patent Publication Nos. 20030130186, 20040110296, and
20040249178; U.S. Pat. No. 6,753,423). Other examples include the
lipophilic moiety, vitamin, polymer, peptide, protein, nucleic
acid, small molecule, oligosaccharide, carbohydrate cluster,
intercalator, minor groove binder, cleaving agent, and
cross-linking agent conjugate molecules described in U.S. Patent
Publication Nos. 20050119470 and 20050107325. Yet other examples
include the 2'-O-alkyl amine, 2'-O-alkoxyalkyl amine, polyamine,
CS-cationic modified pyrimidine, cationic peptide, guanidinium
group, amidininium group, cationic amino acid conjugate molecules
described in U.S. Patent Publication No. 20050153337. Additional
examples include the hydrophobic group, membrane active compound,
cell penetrating compound, cell targeting signal, interaction
modifier, and steric stabilizer conjugate molecules described in
U.S. Patent Publication No. 20040167090. Further examples include
the conjugate molecules described in U.S. Patent Publication No.
20050239739. The type of conjugate used and the extent of
conjugation to the siRNA molecule can be evaluated for improved
pharmacokinetic profiles, bioavailability, and/or stability of the
siRNA while retaining RNAi activity. As such, one skilled in the
art can screen siRNA molecules having various conjugates attached
thereto to identify ones having improved properties and RNAi
activity using any of a variety of well-known in vitro cell culture
or in vivo animal models.
V. Additional Carrier Systems
[0181] Non-limiting examples of additional lipid-based carrier
systems suitable for use in the present invention include
lipoplexes (see, e.g., U.S. Patent Publication No. 20030203865; and
Zhang et al., J. Control Release, 100:165-180 (2004)), pH-sensitive
lipoplexes (see, e.g., U.S. Patent Publication No. 20020192275),
reversibly masked lipoplexes (see, e.g., U.S. Patent Publication
Nos. 20030180950), cationic lipid-based compositions (see, e.g.,
U.S. Pat. No. 6,756,054; and U.S. Patent Publication No.
20050234232), cationic liposomes (see, e.g., U.S. Patent
Publication Nos. 20030229040, 20020160038, and 20020012998; U.S.
Pat. No. 5,908,635; and PCT Publication No. WO 01/72283), anionic
liposomes (see, e.g., U.S. Patent Publication No. 20030026831),
pH-sensitive liposomes (see, e.g., U.S. Patent Publication No.
20020192274; and AU 2003210303), antibody-coated liposomes (see,
e.g., U.S. Patent Publication No. 20030108597; and PCT Publication
No. WO 00/50008), cell-type specific liposomes (see, e.g., U.S.
Patent Publication No. 20030198664), liposomes containing nucleic
acid and peptides (see, e.g., U.S. Pat. No. 6,207,456), liposomes
containing lipids derivatized with releasable hydrophilic polymers
(see, e.g., U.S. Patent Publication No. 20030031704),
lipid-entrapped nucleic acid (see, e.g., PCT Publication Nos. WO
03/057190 and WO 03/059322), lipid-encapsulated nucleic acid (see,
e.g., U.S. Patent Publication No. 20030129221; and U.S. Pat. No.
5,756,122), other liposomal compositions (see, e.g., U.S. Patent
Publication Nos. 20030035829 and 20030072794; and U.S. Pat. No.
6,200,599), stabilized mixtures of liposomes and emulsions (see,
e.g., EP1304160), emulsion compositions (see, e.g., U.S. Pat. No.
6,747,014), and nucleic acid micro-emulsions (see, e.g., U.S.
Patent Publication No. 20050037086).
[0182] Examples of polymer-based carrier systems suitable for use
in the present invention include, but are not limited to, cationic
polymer-nucleic acid complexes (i.e., polyplexes). To form a
polyplex, a nucleic acid (e.g., siRNA) is typically complexed with
a cationic polymer having a linear, branched, star, or dendritic
polymeric structure that condenses the nucleic acid into positively
charged particles capable of interacting with anionic proteoglycans
at the cell surface and entering cells by endocytosis. In some
embodiments, the polyplex comprises nucleic acid (e.g., siRNA)
complexed with a cationic polymer such as polyethylenimine (PEI)
(see, e.g., U.S. Pat. No. 6,013,240; commercially available from
Qbiogene, Inc. (Carlsbad, Calif.) as In vivo jetPEI.TM., a linear
form of PEI), polypropylenimine (PPI), polyvinylpyrrolidone (PVP),
poly-L-lysine (PLL), diethylaminoethyl (DEAE)-dextran,
poly(.beta.-amino ester) (PAE) polymers (see, e.g., Lynn et al., J.
Am. Chem. Soc., 123:8155-8156 (2001)), chitosan, polyamidoamine
(PAMAM) dendrimers (see, e.g., Kukowska-Latallo et al., Proc. Natl.
Acad. Sci. USA, 93:4897-4902 (1996)), porphyrin (see, e.g., U.S.
Pat. No. 6,620,805), polyvinylether (see, e.g., U.S. Patent
Publication No. 20040156909), polycyclic amidinium (see, e.g., U.S.
Patent Publication No. 20030220289), other polymers comprising
primary amine, imine, guanidine, and/or imidazole groups (see,
e.g., U.S. Pat. No. 6,013,240; PCT Publication No. WO/9602655; PCT
Publication No. WO95/21931; Zhang et al., J. Control Release,
100:165-180 (2004); and Tiera et al., Curr. Gene Ther., 6:59-71
(2006)), and a mixture thereof. In other embodiments, the polyplex
comprises cationic polymer-nucleic acid complexes as described in
U.S. Patent Publication Nos. 20060211643, 20050222064, 20030125281,
and 20030185890, and PCT Publication No. WO 03/066069;
biodegradable poly(.beta.-amino ester) polymer-nucleic acid
complexes as described in U.S. Patent Publication No. 20040071654;
microparticles containing polymeric matrices as described in U.S.
Patent Publication No. 20040142475; other microparticle
compositions as described in U.S. Patent Publication No.
20030157030; condensed nucleic acid complexes as described in U.S.
Patent Publication No. 20050123600; and nanocapsule and
microcapsule compositions as described in AU 2002358514 and PCT
Publication No. WO 02/096551.
[0183] In certain instances, the nucleic acid (e.g., siRNA) may be
complexed with cyclodextrin or a polymer thereof. Non-limiting
examples of cyclodextrin-based carrier systems include the
cyclodextrin-modified polymer-nucleic acid complexes described in
U.S. Patent Publication No. 20040087024; the linear cyclodextrin
copolymer-nucleic acid complexes described in U.S. Pat. Nos.
6,509,323, 6,884,789, and 7,091,192; and the cyclodextrin
polymer-complexing agent-nucleic acid complexes described in U.S.
Pat. No. 7,018,609. In certain other instances, the nucleic acid
(e.g., siRNA) may be complexed with a peptide or polypeptide. An
example of a protein-based carrier system includes, but is not
limited to, the cationic oligopeptide-nucleic acid complex
described in PCT Publication No. WO95/21931.
VI. Preparation of SNALPs
[0184] The present invention provides a method of preparing
serum-stable nucleic acid-lipid particles in which the siRNA,
plasmid or other nucleic acid is encapsulated in a lipid bilayer
and is protected from degradation. The particles made by the
methods of this invention typically have a size of about 50 nm to
about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110
nm, or about 70 to about 90 nm. The particles can be formed by any
method known in the art including, but not limited to: a continuous
mixing method, a detergent dialysis method, or a modification of a
reverse-phase method which utilizes organic solvents to provide a
single phase during mixing of the components.
[0185] In preferred embodiments, the cationic lipids are lipids of
Formula I and II or combinations thereof. In other preferred
embodiments, the noncationic lipids are ESM, DOPE, DOPC, DPPE,
DMPE, 16:0 Monomethyl Phosphatidylethanolamine, 16:0 Dimethyl
Phosphatidylethanolamine, 18:1 Trans Phosphatidylethanolamine, 18:0
18:1 Phosphatidylethanolamine (SOPE),
1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE), 16:0
18:1 Phosphatidylethanolamine, DSPE, polyethylene glycol-based
polymers (e.g., PEG 2000, PEG 5000, PEG-modified diacylglycerols,
or PEG-modified dialkyloxypropyls), distearoylphosphatidylcholine
(DSPC), cholesterol, or combinations thereof. In still other
preferred embodiments, the organic solvents are methanol,
chloroform, methylene chloride, ethanol, diethyl ether or
combinations thereof.
[0186] In a particularly preferred embodiment, the nucleic acid is
an siRNA molecule; the cationic lipid is a lipid of Formula I or II
or combinations thereof; the noncationic lipid is ESM, DOPE,
PEG-DAAs, distearoylphosphatidylcholine (DSPC), cholesterol, or
combinations thereof (e.g. DSPC and PEG-DAAs); and the organic
solvent is methanol, chloroform, methylene chloride, ethanol,
diethyl ether or combinations thereof.
[0187] In a particularly preferred embodiment, the present
invention provides for nucleic acid-lipid particles produced via a
continuous mixing method, e.g., process that includes providing an
aqueous solution comprising a nucleic acid such as an siRNA or a
plasmid, in a first reservoir, and providing an organic lipid
solution in a second reservoir, and mixing the aqueous solution
with the organic lipid solution such that the organic lipid
solution mixes with the aqueous solution so as to substantially
instantaneously produce a liposome encapsulating the nucleic acid
(e.g., siRNA). This process and the apparatus for carrying this
process is described in detail in U.S. Patent Publication No.
20040142025.
[0188] The action of continuously introducing lipid and buffer
solutions into a mixing environment, such as in a mixing chamber,
causes a continuous dilution of the lipid solution with the buffer
solution, thereby producing a liposome substantially
instantaneously upon mixing. As used herein, the phrase
"continuously diluting a lipid solution with a buffer solution"
(and variations) generally means that the lipid solution is diluted
sufficiently rapidly in a hydration process with sufficient force
to effectuate vesicle generation. By mixing the aqueous solution
comprising a nucleic acid with the organic lipid solution, the
organic lipid solution undergoes a continuous stepwise dilution in
the presence of the buffer solution (i.e., aqueous solution) to
produce a nucleic acid-lipid particle.
[0189] In another embodiment, the present invention provides for
nucleic acid-lipid particles produced via a direct dilution process
that includes forming a liposome solution and immediately and
directly introducing the liposome solution into a collection vessel
containing a controlled amount of dilution buffer. In preferred
aspects, the collection vessel includes one or more elements
configured to stir the contents of the collection vessel to
facilitate dilution. In one aspect, the amount of dilution buffer
present in the collection vessel is substantially equal to the
volume of liposome solution introduced thereto. As an example,
liposome solution in 45% ethanol when introduced into the
collection vessel containing an equal volume of aqueous solution
will advantageously yield smaller particles in about 22.5%, about
20%, or about 15% ethanol.
[0190] In even another embodiment, the present invention provides
for nucleic acid-lipid particles produced via a direct dilution
process in which a third reservoir containing dilution buffer is
fluidly coupled to a second mixing region. In this embodiment, the
liposome solution formed in a first mixing region is immediately
and directly mixed with dilution buffer in the second mixing
region. In preferred aspects, the second mixing region includes a
T-connector arranged so that the liposome solution and the dilution
buffer flows meet as opposing 180.degree. flows, however,
connectors providing shallower angles can be used, e.g., 27.degree.
to about 180.degree.. A pump mechanism delivers a controllable flow
of buffer to the second mixing region. In one aspect, the flow rate
of dilution buffer provided to the second mixing region is
controlled to be substantially equal to the flow rate of liposome
solution introduced thereto from the first mixing region. This
embodiment advantageously allows for more control of the flow of
dilution buffer mixing with the liposome solution in the second
mixing region, and therefore also the concentration of liposome
solution in buffer throughout the second mixing process. Such
control of the dilution buffer flow rate advantageously allows for
small particle size formation at reduced concentrations.
[0191] These processes and the apparati for carrying these direct
dilution processes is described in detail in U.S. Provisional
Patent Application No. 60/703,380 filed Jul. 27, 2005 (Systems and
Methods for Manufacturing Liposomes, Attorney Docket No.
020801-005300US), which is incorporated herein by reference.
[0192] The serum-stable nucleic acid-lipid particles formed using
the continuous mixing method typically have a size of from about 50
nm to about 150 nm, about 100 nm to about 130 nm, about 110 nm to
about 115 nm, about 65 nm to about 95 nm, or about 50 nm to about
75 nm. The particles thus formed do not aggregate and are
optionally sized to achieve a uniform particle size.
[0193] In some embodiments, the particles are formed using
detergent dialysis. Without intending to be bound by any particular
mechanism of formation, a plasmid or other nucleic acid (e.g.,
siRNA) is contacted with a detergent solution of cationic lipids to
form a coated nucleic acid complex. These coated nucleic acids can
aggregate and precipitate. However, the presence of a detergent
reduces this aggregation and allows the coated nucleic acids to
react with excess lipids (typically, non-cationic lipids) to form
particles in which the plasmid or other nucleic acid is
encapsulated in a lipid bilayer. Thus, the present invention
provides a method for the preparation of serum-stable nucleic
acid-lipid particles, comprising: [0194] (a) combining a nucleic
acid with cationic lipids in a detergent solution to form a coated
nucleic acid-lipid complex; [0195] (b) contacting non-cationic
lipids with the coated nucleic acid-lipid complex to form a
detergent solution comprising a nucleic acid-lipid complex and
non-cationic lipids; and [0196] (c) dialyzing the detergent
solution of step (b) to provide a solution of serum-stable nucleic
acid-lipid particles, wherein the nucleic acid is encapsulated in a
lipid bilayer and the particles are serum-stable and have a size of
from about 50 to about 150 nm.
[0197] An initial solution of coated nucleic acid-lipid complexes
is formed by combining the nucleic acid with the cationic lipids in
a detergent solution.
[0198] In these embodiments, the detergent solution is preferably
an aqueous solution of a neutral detergent having a critical
micelle concentration of 15-300 mM, more preferably 20-50 mM.
Examples of suitable detergents include, for example,
N,N'-((octanoylimino)-bis-(trimethylene))-bis-(D-gluconamide)
(BIGCHAP); BRIJ 35; Deoxy-BIGCHAP; dodecylpoly(ethylene glycol)
ether; Tween 20; Tween 40; Tween 60; Tween 80; Tween 85; Mega 8;
Mega 9; Zwittergent.RTM. 3-08; Zwittergent.RTM. 3-10; Triton X-405;
hexyl-, heptyl-, octyl- and nonyl-.beta.-D-glucopyranoside; and
heptylthioglucopyranoside; with octyl .beta.-D-glucopyranoside and
Tween-20 being the most preferred. The concentration of detergent
in the detergent solution is typically about 100 mM to about 2 M,
preferably from about 200 mM to about 1.5 M.
[0199] The cationic lipids and nucleic acids will typically be
combined to produce a charge ratio (+/-) of about 1:1 to about
20:1, in a ratio of about 1:1 to about 12:1, or in a ratio of about
2:1 to about 6:1. Additionally, the overall concentration of
nucleic acid in solution will typically be from about 25 .mu.g/mL
to about 1 mg/mL, from about 25 .mu.g/mL to about 200 .mu.g/mL, or
from about 50 .mu.g/mL to about 100 .mu.g/mL. The combination of
nucleic acids and cationic lipids in detergent solution is kept,
typically at room temperature, for a period of time which is
sufficient for the coated complexes to form. Alternatively, the
nucleic acids and cationic lipids can be combined in the detergent
solution and warmed to temperatures of up to about 37.degree. C.,
about 50.degree. C., about 60.degree. C., or about 70.degree. C.
For nucleic acids which are particularly sensitive to temperature,
the coated complexes can be formed at lower temperatures, typically
down to about 4.degree. C.
[0200] In some embodiments, the nucleic acid to lipid ratios
(mass/mass ratios) in a formed nucleic acid-lipid particle will
range from about 0.01 to about 0.2, from about 0.03 to about 0.01
or about 0.01 to about 0.08. The ratio of the starting materials
also falls within this range. In another preferred embodiment, the
nucleic acid-lipid particle preparation uses about 400 .mu.g
nucleic acid per 10 mg total lipid or a nucleic acid to lipid ratio
of about 0.01 to about 0.08 or about 0.04, which corresponds to
1.25 mg of total lipid per 50 .mu.g of nucleic acid.
[0201] The detergent solution of the coated nucleic acid-lipid
complexes is then contacted with non-cationic lipids to provide a
detergent solution of nucleic acid-lipid complexes and non-cationic
lipids. The non-cationic lipids which are useful in this step
include, diacylphosphatidylcholine, diacylphosphatidylethanolamine,
ceramide, sphingomyelin, cephalin, cardiolipin, and cerebrosides.
In preferred embodiments, the non-cationic lipids are
diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide
or sphingomyelin. The acyl groups in these lipids are preferably
acyl groups derived from fatty acids having C.sub.10-C.sub.24
carbon chains. More preferably the acyl groups are lauroyl,
myristoyl, palmitoyl, stearoyl or oleoyl. In particularly preferred
embodiments, the non-cationic lipid will be
1,2-sn-dioleoylphosphatidylethanolamine (DOPE), palmitoyl oleoyl
phosphatidylcholine (POPC), egg phosphatidylcholine (EPC),
distearoylphosphatidylcholine (DSPC), cholesterol, or a mixture
thereof. In the most preferred embodiments, the nucleic acid-lipid
particles will be fusogenic particles with enhanced properties in
vivo and the non-cationic lipid will be DSPC or DOPE. In addition,
the nucleic acid-lipid particles of the present invention may
further comprise cholesterol. In other preferred embodiments, the
non-cationic lipids will further comprise polyethylene glycol-based
polymers such as PEG 2000, PEG 5000 and polyethylene glycol
conjugated to a diacylglycerol, a ceramide or a phospholipid, as
described in U.S. Pat. No. 5,820,873 and U.S. Patent Publication
No. 20030077829. In further preferred embodiments, the non-cationic
lipids will further comprise polyethylene glycol-based polymers
such as PEG 2000, PEG 5000 and polyethylene glycol conjugated to a
dialkyloxypropyl.
[0202] Following formation of the detergent solution of nucleic
acid-lipid complexes and non-cationic lipids, the detergent is
removed, preferably by dialysis. The removal of the detergent
results in the formation of a lipid-bilayer which surrounds the
nucleic acid providing serum-stable nucleic acid-lipid particles
which have a size of from about 50 nm to about 150 nm, more
typically about 60 nm to about 130 nm, more typically about 70 nm
to about 110 nm, most typically about 70 to about 90 nm. The
particles thus formed do not aggregate and are optionally sized to
achieve a uniform particle size.
[0203] The serum-stable nucleic acid-lipid particles can be sized
by any of the methods available for sizing liposomes. The sizing
may be conducted in order to achieve a desired size range and
relatively narrow distribution of particle sizes.
[0204] Several techniques are available for sizing the particles to
a desired size. One sizing method, used for liposomes and equally
applicable to the present particles is described in U.S. Pat. No.
4,737,323. Sonicating a particle suspension either by bath or probe
sonication produces a progressive size reduction down to particles
of less than about 50 nm in size. Homogenization is another method
which relies on shearing energy to fragment larger particles into
smaller ones. In a typical homogenization procedure, particles are
recirculated through a standard emulsion homogenizer until selected
particle sizes, typically between about 60 and 80 nm, are observed.
In both methods, the particle size distribution can be monitored by
conventional laser-beam particle size discrimination, or QELS.
[0205] Extrusion of the particles through a small-pore
polycarbonate membrane or an asymmetric ceramic membrane is also an
effective method for reducing particle sizes to a relatively
well-defined size distribution. Typically, the suspension is cycled
through the membrane one or more times until the desired particle
size distribution is achieved. The particles may be extruded
through successively smaller-pore membranes, to achieve a gradual
reduction in size.
[0206] In another group of embodiments, the present invention
provides a method for the preparation of serum-stable nucleic
acid-lipid particles, comprising: [0207] (a) preparing a mixture
comprising cationic lipids and non-cationic lipids in an organic
solvent; [0208] (b) contacting an aqueous solution of nucleic acid
with said mixture in step (a) to provide a clear single phase; and
[0209] (c) removing said organic solvent to provide a suspension of
nucleic acid-lipid particles, wherein said nucleic acid is
encapsulated in a lipid bilayer, and said particles are stable in
serum and have a size of from about 50 to about 150 nm.
[0210] The nucleic acids (or plasmids), cationic lipids and
non-cationic lipids which are useful in this group of embodiments
are as described for the detergent dialysis methods above.
[0211] The selection of an organic solvent will typically involve
consideration of solvent polarity and the ease with which the
solvent can be removed at the later stages of particle formation.
The organic solvent, which is also used as a solubilizing agent, is
in an amount sufficient to provide a clear single phase mixture of
nucleic acid and lipids. Suitable solvents include, but are not
limited to, chloroform, dichloromethane, diethylether, cyclohexane,
cyclopentane, benzene, toluene, methanol, or other aliphatic
alcohols such as propanol, isopropanol, butanol, tert-butanol,
iso-butanol, pentanol and hexanol. Combinations of two or more
solvents may also be used in the present invention.
[0212] Contacting the nucleic acid with the organic solution of
cationic and non-cationic lipids is accomplished by mixing together
a first solution of nucleic acid, which is typically an aqueous
solution, and a second organic solution of the lipids. One of skill
in the art will understand that this mixing can take place by any
number of methods, for example by mechanical means such as by using
vortex mixers.
[0213] After the nucleic acid has been contacted with the organic
solution of lipids, the organic solvent is removed, thus forming an
aqueous suspension of serum-stable nucleic acid-lipid particles.
The methods used to remove the organic solvent will typically
involve evaporation at reduced pressures or blowing a stream of
inert gas (e.g., nitrogen or argon) across the mixture.
[0214] The serum-stable nucleic acid-lipid particles thus formed
will typically be sized from about 50 nm to about 150 nm, more
typically about 60 nm to about 130 nm, more typically about 70 nm
to about 110 nm, most typically about 70 to about 90 nm. To achieve
further size reduction or homogeneity of size in the particles,
sizing can be conducted as described above.
[0215] In other embodiments, the methods will further comprise
adding nonlipid polycations which are useful to effect the delivery
to cells using the present compositions. Examples of suitable
nonlipid polycations include, but are limited to, hexadimethrine
bromide (sold under the brandname POLYBRENE.RTM., from Aldrich
Chemical Co., Milwaukee, Wis., USA) or other salts of
heaxadimethrine. Other suitable polycations include, for example,
salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine,
poly-D-lysine, polyallylamine and polyethyleneimine.
[0216] In certain embodiments, the formation of the nucleic
acid-lipid particles can be carried out either in a mono-phase
system (e.g., a Bligh and Dyer monophase or similar mixture of
aqueous and organic solvents) or in a two-phase system with
suitable mixing.
[0217] When formation of the complexes is carried out in a
mono-phase system, the cationic lipids and nucleic acids are each
dissolved in a volume of the mono-phase mixture. Combination of the
two solutions provides a single mixture in which the complexes
form. Alternatively, the complexes can form in two-phase mixtures
in which the cationic lipids bind to the nucleic acid (which is
present in the aqueous phase), and "pull" it into the organic
phase.
[0218] In another embodiment, the present invention provides a
method for the preparation of nucleic acid-lipid particles,
comprising: [0219] (a) contacting nucleic acids with a solution
comprising non-cationic lipids and a detergent to form a nucleic
acid-lipid mixture; [0220] (b) contacting cationic lipids with the
nucleic acid-lipid mixture to neutralize a portion of the negative
charge of the nucleic acids and form a charge-neutralized mixture
of nucleic acids and lipids; and [0221] (c) removing the detergent
from the charge-neutralized mixture to provide the nucleic
acid-lipid particles in which the nucleic acids are protected from
degradation.
[0222] In one group of embodiments, the solution of non-cationic
lipids and detergent is an aqueous solution. Contacting the nucleic
acids with the solution of non-cationic lipids and detergent is
typically accomplished by mixing together a first solution of
nucleic acids and a second solution of the lipids and detergent.
One of skill in the art will understand that this mixing can take
place by any number of methods, for example, by mechanical means
such as by using vortex mixers. Preferably, the nucleic acid
solution is also a detergent solution. The amount of non-cationic
lipid which is used in the present method is typically determined
based on the amount of cationic lipid used, and is typically of
from about 0.2 to 5 times the amount of cationic lipid, preferably
from about 0.5 to about 2 times the amount of cationic lipid
used.
[0223] In some embodiments, the nucleic acids are precondensed as
described in, e.g., U.S. patent application Ser. No.
09/744,103.
[0224] The nucleic acid-lipid mixture thus formed is contacted with
cationic lipids to neutralize a portion of the negative charge
which is associated with the nucleic acids (or other polyanionic
materials) present. The amount of cationic lipids used will
typically be sufficient to neutralize at least 50% of the negative
charge of the nucleic acid. Preferably, the negative charge will be
at least 70% neutralized, more preferably at least 90% neutralized.
Cationic lipids which are useful in the present invention, include,
for example, DLinDMA and, DLenDMA. These lipids and related analogs
have been described in U.S. patent application Ser. No. 11/148,430,
filed Jun. 7, 2005.
[0225] Contacting the cationic lipids with the nucleic acid-lipid
mixture can be accomplished by any of a number of techniques,
preferably by mixing together a solution of the cationic lipid and
a solution containing the nucleic acid-lipid mixture. Upon mixing
the two solutions (or contacting in any other manner), a portion of
the negative charge associated with the nucleic acid is
neutralized. Nevertheless, the nucleic acid remains in an
uncondensed state and acquires hydrophilic characteristics.
[0226] After the cationic lipids have been contacted with the
nucleic acid-lipid mixture, the detergent (or combination of
detergent and organic solvent) is removed, thus forming the nucleic
acid-lipid particles. The methods used to remove the detergent will
typically involve dialysis. When organic solvents are present,
removal is typically accomplished by evaporation at reduced
pressures or by blowing a stream of inert gas (e.g., nitrogen or
argon) across the mixture.
[0227] The particles thus formed will typically be sized from about
50 nm to several microns, more typically about 50 nm to about 150
nm, more typically about 60 nm to about 130 nm, more typically
about 70 nm to about 110 nm, most typically about 70 to about 90
nm. To achieve further size reduction or homogeneity of size in the
particles, the nucleic acid-lipid particles can be sonicated,
filtered or subjected to other sizing techniques which are used in
liposomal formulations and are known to those of skill in the
art.
[0228] In other embodiments, the methods will further comprise
adding nonlipid polycations which are useful to effect the
lipofection of cells using the present compositions. Examples of
suitable nonlipid polycations include, hexadimethrine bromide (sold
under the brandname POLYBRENE.RTM., from Aldrich Chemical Co.,
Milwaukee, Wis., USA) or other salts of hexadimethrine. Other
suitable polycations include, for example, salts of
poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine,
polyallylamine and polyethyleneimine. Addition of these salts is
preferably after the particles have been formed.
[0229] In another aspect, the present invention provides methods
for the preparation of nucleic acid-lipid particles, comprising:
[0230] (a) contacting an amount of cationic lipids with nucleic
acids in a solution; the solution comprising from about 15-35%
water and about 65-85% organic solvent and the amount of cationic
lipids being sufficient to produce a +/-charge ratio of from about
0.85 to about 2.0, to provide a hydrophobic nucleic acid-lipid
complex; [0231] (b) contacting the hydrophobic, nucleic acid-lipid
complex in solution with non-cationic lipids, to provide a nucleic
acid-lipid mixture; and [0232] (c) removing the organic solvents
from the nucleic acid-lipid mixture to provide nucleic acid-lipid
particles in which the nucleic acids are protected from
degradation.
[0233] The nucleic acids, non-cationic lipids, cationic lipids and
organic solvents which are useful in this aspect of the invention
are the same as those described for the methods above which used
detergents. In one group of embodiments, the solution of step (a)
is a mono-phase. In another group of embodiments, the solution of
step (a) is two-phase.
[0234] In preferred embodiments, the non-cationic lipids are ESM,
DOPE, DOPC, polyethylene glycol-based polymers (e.g., PEG 2000, PEG
5000, PEG-modified diacylglycerols, or PEG-modified
dialkyloxypropyls), distearoylphosphatidylcholine (DSPC), DPPE,
DMPE, 16:0 Monomethyl Phosphatidylethanolamine, 16:0 Dimethyl
Phosphatidylethanolamine, 18:1 Trans Phosphatidylethanolamine, 18:0
18:1 Phosphatidylethanolamine (SOPE),
1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE), 16:0
18:1 Phosphatidylethanolamine, DSPE, cholesterol, or combinations
thereof. In still other preferred embodiments, the organic solvents
are methanol, chloroform, methylene chloride, ethanol, diethyl
ether or combinations thereof.
[0235] In one embodiment, the nucleic acid is a plasmid from which
an interfering RNA is transcribed; the cationic lipid is DLinDMA,
DLenDMA, DODAC, DDAB, DOTMA, DOSPA, DMRIE, DOGS or combinations
thereof; the non-cationic lipid is ESM, DOPE, DAG-PEGs,
distearoylphosphatidylcholine (DSPC), DPPE, DMPE, 16:0 Monomethyl
Phosphatidylethanolamine, 16:0 Dimethyl Phosphatidylethanolamine,
18:1 Trans Phosphatidylethanolamine, 18:0 18:1
Phosphatidylethanolamine (SOPE),
1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE), 16:0
18:1 Phosphatidylethanolamine DSPE, cholesterol, or combinations
thereof (e.g. DSPC and PEG-DAA); and the organic solvent is
methanol, chloroform, methylene chloride, ethanol, diethyl ether or
combinations thereof.
[0236] As above, contacting the nucleic acids with the cationic
lipids is typically accomplished by mixing together a first
solution of nucleic acids and a second solution of the lipids,
preferably by mechanical means such as by using vortex mixers. The
resulting mixture contains complexes as described above. These
complexes are then converted to particles by the addition of
non-cationic lipids and the removal of the organic solvent. The
addition of the non-cationic lipids is typically accomplished by
simply adding a solution of the non-cationic lipids to the mixture
containing the complexes. A reverse addition can also be used.
Subsequent removal of organic solvents can be accomplished by
methods known to those of skill in the art and also described
above.
[0237] The amount of non-cationic lipids which is used in this
aspect of the invention is typically an amount of from about 0.2 to
about 15 times the amount (on a mole basis) of cationic lipids
which was used to provide the charge-neutralized nucleic acid-lipid
complex. Preferably, the amount is from about 0.5 to about 9 times
the amount of cationic lipids used.
[0238] In yet another aspect, the present invention provides
nucleic acid-lipid particles which are prepared by the methods
described above. In these embodiments, the nucleic acid-lipid
particles are either net charge neutral or carry an overall charge
which provides the particles with greater gene lipofection
activity. Preferably, the nucleic acid component of the particles
is a nucleic acid which interferes with the production of an
undesired protein. In some embodiments, the nucleic acid comprises
an interfering RNA, the non-cationic lipid is egg sphingomyelin and
the cationic lipid is DLinDMA or DLenDMA. In some embodiments, the
nucleic acid comprises an interfering RNA, the non-cationic lipid
is a mixture of DSPC and cholesterol, and the cationic lipid is
DLinDMA or DLenDMA. In other preferred embodiments, the
non-cationic lipid may further comprise cholesterol.
[0239] A variety of general methods for making SNALP-CPLs
(CPL-containing SNALPs) are discussed herein. Two general
techniques include "post-insertion" technique, that is, insertion
of a CPL into for example, a pre-formed SNALP, and the "standard"
technique, wherein the CPL is included in the lipid mixture during
for example, the SNALP formation steps. The post-insertion
technique results in SNALPs having CPLs mainly in the external face
of the SNALP bilayer membrane, whereas standard techniques provide
SNALPs having CPLs on both internal and external faces. The method
is especially useful for vesicles made from phospholipids (which
can contain cholesterol) and also for vesicles containing
PEG-lipids (such as PEG-DAAs and PEG-DAGs). Methods of making
SNALP-CPL, are taught, for example, in U.S. Pat. Nos. 5,705,385,
6,586,410, 5,981,501 6,534,484; 6,852,334; U.S. Patent Publication
No. 20020072121; and WO 00/62813.
VII. Kits
[0240] The present invention also provides nucleic acid-lipid
particles in kit form. The kit will typically be comprised of a
container which is compartmentalized for holding the various
elements of the nucleic acid-lipid particles. The kit will contain
the compositions of the present inventions, preferably in
dehydrated form, with instructions for their rehydration and
administration. In still other embodiments, the particles and/or
compositions comprising the particles will have a targeting moiety
attached to the surface of the particle. Methods of attaching
targeting moieties (e.g., antibodies, proteins) to lipids (such as
those used in the present particles) are known to those of skill in
the art.
VIII. Administration of Nucleic Acid-Lipid Particles
[0241] Once formed, the serum-stable nucleic acid-lipid particles
of the present invention are useful for the introduction of nucleic
acids (i.e., siRNA that silences expression of gene expressed in
cancer such as an Eg5, EGFR and/or XIAP gene) into cells.
Accordingly, the present invention also provides methods for
introducing a nucleic acids (e.g., a plasmid or and siRNA) into a
cell. The methods are carried out in vitro or in vivo by first
forming the particles as described above and then contacting the
particles with the cells for a period of time sufficient for
delivery of the nucleic acid to the cell to occur.
[0242] The nucleic acid-lipid particles of the present invention
can be adsorbed to almost any cell type with which they are mixed
or contacted. Once adsorbed, the particles can either be
endocytosed by a portion of the cells, exchange lipids with cell
membranes, or fuse with the cells. Transfer or incorporation of the
nucleic acid portion of the particle can take place via any one of
these pathways. In particular, when fusion takes place, the
particle membrane is integrated into the cell membrane and the
contents of the particle combine with the intracellular fluid.
[0243] The nucleic acid-lipid particles of the present invention
can be administered either alone or in mixture with a
physiologically-acceptable carrier (such as physiological saline or
phosphate buffer) selected in accordance with the route of
administration and standard pharmaceutical practice. Generally,
normal saline will be employed as the pharmaceutically acceptable
carrier. Other suitable carriers include, e.g., water, buffered
water, 0.4% saline, 0.3% glycine, and the like, including
glycoproteins for enhanced stability, such as albumin, lipoprotein,
globulin, etc.
[0244] The pharmaceutical carrier is generally added following
particle formation. Thus, after the particle is formed, the
particle can be diluted into pharmaceutically acceptable carriers
such as normal saline.
[0245] The concentration of particles in the pharmaceutical
formulations can vary widely, i.e., from less than about 0.05%,
usually at or at least about 2-5% to as much as 10 to 30% by weight
and will be selected primarily by fluid volumes, viscosities, etc.,
in accordance with the particular mode of administration selected.
For example, the concentration may be increased to lower the fluid
load associated with treatment. This may be particularly desirable
in patients having atherosclerosis-associated congestive heart
failure or severe hypertension. Alternatively, particles composed
of irritating lipids may be diluted to low concentrations to lessen
inflammation at the site of administration.
[0246] The pharmaceutical compositions of the present invention may
be sterilized by conventional, well known sterilization techniques.
Aqueous solutions can be packaged for use or filtered under aseptic
conditions and lyophilized, the lyophilized preparation being
combined with a sterile aqueous solution prior to administration.
The compositions can contain pharmaceutically acceptable auxiliary
substances as required to approximate physiological conditions,
such as pH adjusting and buffering agents, tonicity adjusting
agents and the like, for example, sodium acetate, sodium lactate,
sodium chloride, potassium chloride, and calcium chloride.
Additionally, the particle suspension may include lipid-protective
agents which protect lipids against free-radical and
lipid-peroxidative damages on storage. Lipophilic free-radical
quenchers, such as alphatocopherol and water-soluble iron-specific
chelators, such as ferrioxamine, are suitable.
[0247] The nucleic acid-lipid particles can be incorporated into a
broad range of topical dosage forms including, but not limited to,
gels, oils, emulsions, topical creams, pastes, ointments, lotions
and the like.
[0248] A. In Vivo Administration
[0249] Systemic delivery for in vivo therapy, i.e., delivery of a
therapeutic nucleic acid to a distal target cell via body systems
such as the circulation, has been achieved using nucleic acid-lipid
particles such as those disclosed in WO 96/40964 and U.S. Pat. Nos.
5,705,385, 5,976,567, 5,981,501 and 6,410,328. This latter format
provides a fully encapsulated nucleic acid-lipid particle that
protects the nucleic acid from nuclease degradation in serum, is
nonimmunogenic, is small in size and is suitable for repeat
dosing.
[0250] For in vivo administration, administration can be in any
manner known in the art, e.g., by injection, oral administration,
inhalation (e.g., intransal or intratracheal), transdermal
application, or rectal administration. Administration can be
accomplished via single or divided doses. The pharmaceutical
compositions can be administered parenterally, i.e.,
intraarticularly, intravenously, intraperitoneally, subcutaneously,
intramuscularly, or intratumorally. In some embodiments, the
pharmaceutical compositions are administered intravenously or
intraperitoneally by a bolus injection (see, e.g., Stadler, et al.,
U.S. Pat. No. 5,286,634) or by pump infusion. Intracellular nucleic
acid delivery has also been discussed in Straubringer, et al.,
Methods Enzymol, Academic Press, New York. 101:512 (1983); Mannino,
et al., Biotechniques 6:682 (1988); Nicolau, et al., Crit. Rev.
Ther. Drug Carrier Syst. 6:239 (1989), and Behr, Acc. Chem. Res.
26:274 (1993). Still other methods of administering lipid based
therapeutics are described in, for example, Rahman et al., U.S.
Pat. No. 3,993,754; Sears, U.S. Pat. No. 4,145,410; Papahadjopoulos
et al., U.S. Pat. No. 4,235,871; Schneider, U.S. Pat. No.
4,224,179; Lenk et al., U.S. Pat. No. 4,522,803; and Fountain et
al., U.S. Pat. No. 4,588,578. The lipid nucleic acid particles can
be administered by direct injection at the site of disease or by
injection at a site distal from the site of disease (see, e.g.,
Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New
York. pp. 70-71 (1994)).
[0251] The compositions of the present invention, either alone or
in combination with other suitable components, can be made into
aerosol formulations (i.e., they can be "nebulized") to be
administered via inhalation (e.g., intranasally or intratracheally)
(see, Brigham, et al., Am. J. Sci. 298(4):278 (1989)). Aerosol
formulations can be placed into pressurized acceptable propellants,
such as dichlorodifluoromethane, propane, nitrogen, and the
like.
[0252] Formulations suitable for parenteral administration, such
as, for example, by intraarticular (in the joints), intravenous,
intramuscular, intradermal, intraperitoneal, and subcutaneous
routes, include aqueous and non-aqueous, isotonic sterile injection
solutions, which can contain antioxidants, buffers, bacteriostats,
and solutes that render the formulation isotonic with the blood of
the intended recipient, and aqueous and non-aqueous sterile
suspensions that can include suspending agents, solubilizers,
thickening agents, stabilizers, and preservatives. In the practice
of this invention, compositions can be administered, for example,
by intravenous infusion, orally, topically, intraperitoneally,
intravesically or intrathecally.
[0253] Formulations suitable for oral administration can consist of
(a) liquid solutions, such as an effective amount of the packaged
nucleic acid suspended in diluents, such as water, saline or PEG
400; (b) capsules, sachets or tablets, each containing a
predetermined amount of the active ingredient, as liquids, solids,
granules or gelatin; (c) suspensions in an appropriate liquid; and
(d) suitable emulsions. Tablet forms can include one or more of
lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn
starch, potato starch, microcrystalline cellulose, gelatin,
colloidal silicon dioxide, talc, magnesium stearate, stearic acid,
and other excipients, colorants, fillers, binders, diluents,
buffering agents, moistening agents, preservatives, flavoring
agents, dyes, disintegrating agents, and pharmaceutically
compatible carriers. Lozenge forms can comprise the active
ingredient in a flavor, e.g., sucrose, as well as pastilles
comprising the active ingredient in an inert base, such as gelatin
and glycerin or sucrose and acacia emulsions, gels, and the like
containing, in addition to the active ingredient, carriers known in
the art.
[0254] Generally, when administered intravenously, the nucleic
acid-lipid formulations are formulated with a suitable
pharmaceutical carrier. Many pharmaceutically acceptable carriers
may be employed in the compositions and methods of the present
invention. Suitable formulations for use in the present invention
are found, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES,
Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985). A
variety of aqueous carriers may be used, for example, water,
buffered water, 0.4% saline, 0.3% glycine, and the like, and may
include glycoproteins for enhanced stability, such as albumin,
lipoprotein, globulin, etc. Generally, normal buffered saline
(135-150 mM NaCl) will be employed as the pharmaceutically
acceptable carrier, but other suitable carriers will suffice. These
compositions can be sterilized by conventional liposomal
sterilization techniques, such as filtration. The compositions may
contain pharmaceutically acceptable auxiliary substances as
required to approximate physiological conditions, such as pH
adjusting and buffering agents, tonicity adjusting agents, wetting
agents and the like, for example, sodium acetate, sodium lactate,
sodium chloride, potassium chloride, calcium chloride, sorbitan
monolaurate, triethanolamine oleate, etc. These compositions can be
sterilized using the techniques referred to above or,
alternatively, they can be produced under sterile conditions. The
resulting aqueous solutions may be packaged for use or filtered
under aseptic conditions and lyophilized, the lyophilized
preparation being combined with a sterile aqueous solution prior to
administration.
[0255] The methods of the present invention may be practiced in a
variety of hosts. Preferred hosts include mammalian species, such
as primates (e.g., humans and chimpanzees as well as other nonhuman
primates), canines, felines, equines, bovines, ovines, caprines,
rodents (e.g., rats and mice), lagomorphs, and swine.
[0256] The amount of particles administered will depend upon the
ratio of nucleic acid to lipid; the particular nucleic acid used,
the disease state being diagnosed; the age, weight, and condition
of the patient and the judgment of the clinician; but will
generally be between about 0.01 and about 50 mg per kilogram of
body weight; preferably between about 0.1 and about 5 mg/kg of body
weight or about 10.sup.8-10.sup.10 particles per injection.
[0257] B. Combination Therapy
[0258] In some embodiments, the nucleic acid-lipid particles
described herein are administered in combination with a second
therapeutic agent for treating or preventing cancer. For example,
the nucleic acid-lipid particles may be administered in conjunction
with any of the standard treatments for cancer including, but not
limited to, chemotherapeutic agents including, e.g., alitretinoin,
altretamine, anastrozole, azathioprine, bicalutamide, busulfan,
capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine,
doxorubicin, epirubicin, etoposide, exemestane, finasteride,
fluorouracil, fulvestrant, gemtuzumab, ozogamicin, hydroxyurea,
ibritumomab, idarubicin, ifosfamide, imatinib, letrozole, megestrol
acetate, methotrexate, mifepristone, paclitaxel, rituximab,
tamoxifen, temozolomide, tretinoin, triptorelin, vincristine, or
vinorelbine, and radiation treatment.
[0259] The nucleic acid-lipid particles and the second therapeutic
agent may be administered simultaneously or sequentially. For
example, the nucleic acid-lipid particles may be administered
first, followed by the second therapeutic agent. Alternatively, the
second therapeutic agent may be administered first, followed by the
nucleic acid-lipid particles. In some cases, the nucleic acid-lipid
particles and the second therapeutic agent are administered in the
same formulation. In other cases the nucleic acid-lipid particles
and nucleic acids and the second therapeutic agent are administered
in different formulations.
[0260] C. Cells for Delivery of Interfering RNA
[0261] The compositions and methods of the present invention are
used to treat a wide variety of cell types, in vivo and in vitro.
Suitable cells include, e.g., hematopoietic precursor (stem) cells,
fibroblasts, keratinocytes, hepatocytes, endothelial cells,
skeletal and smooth muscle cells, osteoblasts, neurons, quiescent
lymphocytes, terminally differentiated cells, slow or noncycling
primary cells, parenchymal cells, lymphoid cells, epithelial cells,
bone cells, and the like.
[0262] In vivo delivery of nucleic acid-lipid particles
encapsulating an interfering RNA is particularly suited for
targeting tumor cells of any cell type. In vivo studies show that
SNALP's accumulate at tumor sites and predominantly transfect tumor
cells. See, Fenske, et al., Methods Enzymol, Academic Press, New
York 346:36 (2002). The methods and compositions can be employed
with cells of a wide variety of vertebrates, including mammals, and
especially those of veterinary importance, e.g, canine, feline,
equine, bovine, ovine, caprine, rodent, lagomorph, swine, etc., in
addition to human cell populations.
[0263] To the extent that tissue culture of cells may be required,
it is well known in the art. Freshney (1994) (Culture of Animal
Cells, a Manual of Basic Technique, third edition Wiley-Liss, New
York), Kuchler et al. (1977) Biochemical Methods in Cell Culture
and Virology, Kuchler, R. J., Dowden, Hutchinson and Ross, Inc.,
and the references cited therein provides a general guide to the
culture of cells. Cultured cell systems often will be in the form
of monolayers of cells, although cell suspensions are also
used.
[0264] D. Detection of SNALPs
[0265] In some embodiments, the nucleic acid-lipid particles are
detectable in the subject 8, 12, 24, 48, 60, 72, or 96 hours, 6, 8,
10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration
of the particles. The presence of the particles can be detected in
the cells, tissues, or other biological samples from the subject.
The particles may be detected, e.g., by direct detection of the
particles, detection of the interfering RNA sequence, detection of
the target sequence of interest (i.e., by detecting expression or
reduced expression of the Eg5, EGFR and/or XIAP sequence of
interest), detection of a target protein of interest (e.g., by
detecting expression or reduced expression of Eg5, EGFR and/or XIAP
protein), detection of a compound modulated directly or indirectly
by the Eg5, EGFR and/or XIAP (e.g., tubulin, phosphor-histones, P13
kinase-AKT, STATS, caspases) or by detection of apoptosis and cell
viability in the subject or a combination thereof.
[0266] 1. Detection of Particles
[0267] Nucleic acid-lipid particles can be detected using any
methods known in the art. For example, a label can be coupled
directly or indirectly to a component of the SNALP or other
lipid-based carrier system using methods well known in the art. A
wide variety of labels can be used, with the choice of label
depending on sensitivity required, ease of conjugation with the
SNALP component, stability requirements, and available
instrumentation and disposal provisions. Suitable labels include,
but are not limited to, spectral labels, such as fluorescent dyes
(e.g., fluorescein and derivatives, such as fluorescein
isothiocyanate (FITC) and Oregon Green.TM.; rhodamine and
derivatives, such Texas red, tetrarhodimine isothiocynate (TRITC),
etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyes.TM., and the
like; radiolabels, such as .sup.3H, .sup.125I, .sup.35S, .sup.14C,
.sup.32P, .sup.33P etc.; enzymes, such as horse radish peroxidase,
alkaline phosphatase, etc.; spectral colorimetric labels, such as
colloidal gold or colored glass or plastic beads, such as
polystyrene, polypropylene, latex, etc. The label can be detected
using any means known in the art.
[0268] 2. Detection of Nucleic Acids
[0269] Nucleic acids (i.e., siRNA that silence expression of an
Eg5, EGFR and/or XIAP gene) are detected and quantified herein by
any of a number of means well known to those of skill in the art.
The detection of nucleic acids proceeds by well known methods such
as Southern analysis, northern analysis, gel electrophoresis, PCR,
radiolabeling, scintillation counting, and affinity chromatography.
Additional analytic biochemical methods such as spectrophotometry,
radiography, electrophoresis, capillary electrophoresis, high
performance liquid chromatography (HPLC), thin layer chromatography
(TLC), hyperdiffusion chromatography, may also be employed
[0270] The selection of a nucleic acid hybridization format is not
critical. A variety of nucleic acid hybridization formats are known
to those skilled in the art. For example, common formats include
sandwich assays and competition or displacement assays.
Hybridization techniques are generally described in "Nucleic Acid
Hybridization, A Practical Approach," Ed. Hames, B. D. and Higgins,
S. J., IRL Press, 1985.
[0271] The sensitivity of the hybridization assays may be enhanced
through use of a nucleic acid amplification system which multiplies
the target nucleic acid being detected. In vitro amplification
techniques suitable for amplifying sequences for use as molecular
probes or for generating nucleic acid fragments for subsequent
subcloning are known. Examples of techniques sufficient to direct
persons of skill through such in vitro amplification methods,
including the polymerase chain reaction (PCR) the ligase chain
reaction (LCR), Q.beta.-replicase amplification and other RNA
polymerase mediated techniques (e.g., NASBA.TM.) are found in
Sambrook, et al., In Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory Press, 2000, and Ausubel et al., SHORT
PROTOCOLS IN MOLECULAR BIOLOGY, eds., Current Protocols, a joint
venture between Greene Publishing Associates, Inc. and John Wiley
& Sons, Inc., (2002), as well as Mullis et al. (1987), U.S.
Pat. No. 4,683,202; PCR Protocols A Guide to Methods and
Applications (Innis et al. eds) Academic Press Inc. San Diego,
Calif. (1990) (Innis); Arnheim & Levinson (Oct. 1, 1990),
C&EN 36; The Journal Of NIH Research, 3:81 (1991); (Kwoh et
al., Proc. Natl. Acad. Sci. USA, 86:1173 (1989); Guatelli et al.,
Proc. Natl. Acad. Sci. USA, 87:1874 (1990); Lomell et al., J. Clin.
Chem., 35:1826 (1989); Landegren et al., Science, 241:1077 (1988);
Van Brunt, Biotechnology, 8:291 (1990); Wu and Wallace, Gene, 4:560
(1989); Barringer et al., Gene, 89:117 (1990), and Sooknanan and
Malek, Biotechnology, 13:563 (1995). Improved methods of cloning in
vitro amplified nucleic acids are described in Wallace et al., U.S.
Pat. No. 5,426,039. Other methods described in the art are the
nucleic acid sequence based amplification (NASBA.TM., Cangene,
Mississauga, Ontario) and Q Beta Replicase systems. These systems
can be used to directly identify mutants where the PCR or LCR
primers are designed to be extended or ligated only when a select
sequence is present. Alternatively, the select sequences can be
generally amplified using, for example, nonspecific PCR primers and
the amplified target region later probed for a specific sequence
indicative of a mutation.
[0272] Oligonucleotides for use as probes, e.g., in in vitro
amplification methods, for use as gene probes, or as inhibitor
components are typically synthesized chemically according to the
solid phase phosphoramidite triester method described by Beaucage
and Caruthers, Tetrahedron Letts., 22(20):1859 1862 (1981), e.g.,
using an automated synthesizer, as described in Needham VanDevanter
et al., Nucleic Acids Res., 12:6159 (1984). Purification of
oligonucleotides, where necessary, is typically performed by either
native acrylamide gel electrophoresis or by anion exchange HPLC as
described in Pearson and Regnier, J. Chrom., 255:137 149 (1983).
The sequence of the synthetic oligonucleotides can be verified
using the chemical degradation method of Maxam and Gilbert (1980)
in Grossman and Moldave (eds.) Academic Press, New York, Methods in
Enzymology, 65:499.
[0273] An alternative means for determining the level of
transcription is in situ hybridization. In situ hybridization
assays are well known and are generally described in Angerer et
al., Methods Enzymol., 152:649 (1987). In an in situ hybridization
assay cells are fixed to a solid support, typically a glass slide.
If DNA is to be probed, the cells are denatured with heat or
alkali. The cells are then contacted with a hybridization solution
at a moderate temperature to permit annealing of specific probes
that are labeled. The probes are preferably labeled with
radioisotopes or fluorescent reporters.
[0274] E. Detection of an Immune Response
[0275] An immune response to induced by the siRNA (i.e., siRNA that
silence expression of an Eg5, EGFR and/or XIAP gene) described
herein can be long-lived and can be detected long after
administration of the siRNA or nucleic acid-lipid particles
containing the siRNA. An immune response to the siRNA can be
detected by using immunoassays that detect the presence or absence
of cytokines and growth factors e.g., produced by responder
cells.
[0276] Suitable immunoassays include the double monoclonal antibody
sandwich immunoassay technique of David et al. (U.S. Pat. No.
4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et
al., in Kirkham and Hunter, eds., Radioimmunoassay Methods, E. and
S. Livingstone, Edinburgh (1970)); the "western blot" method of
Gordon et al. (U.S. Pat. No. 4,452,901); immunoprecipitation of
labeled ligand (Brown et al. (1980) J. Biol. Chem. 255:4980-4983);
enzyme-linked immunosorbent assays (ELISA) as described, for
example, by Raines et al. (1982) J. Biol. Chem. 257:5154-5160;
immunocytochemical techniques, including the use of fluorochromes
(Brooks et al. (1980) Clin. Exp. Immunol. 39:477); and
neutralization of activity (Bowen-Pope et al. (1984) Proc. Natl.
Acad. Sci. USA 81:2396-2400). In addition to the immunoassays
described above, a number of other immunoassays are available,
including those described in U.S. Pat. Nos. 3,817,827; 3,850,752;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and
4,098,876.
[0277] Monoclonal antibodies that specifically bind cytokines and
growth factors (e.g., Il-6, IL-12, TNF-.alpha., IFN-.alpha., and
IFN-.gamma. can be generated using methods known in the art (see,
e.g., Kohler and Milstein, Nature 256: 495-497 (1975) and Harlow
and Lane, ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor
Publication, New York (1999)). Generation of monoclonal antibodies
has been previously described and can be accomplished by any means
known in the art. (Buhring et al. in Hybridoma 1991, Vol. 10, No.
1, pp. 77-78). For example, an animal such as a guinea pig or rat,
preferably a mouse is immunized with an immunogenic polypeptide,
the antibody-producing cells, preferably splenic lymphocytes, are
collected and fused to a stable, immortalized cell line, preferably
a myeloma cell line, to produce hybridoma cells which are then
isolated and cloned. (U.S. Pat. No. 6,156,882). In some methods,
the monoclonal antibody is labeled to facilitate detection.
[0278] The invention will be described in greater detail by way of
specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the invention
in any manner. Those of skill in the art will readily recognize a
variety of noncritical parameters which can be changed or modified
to yield essentially the same results.
EXAMPLES
[0279] The following examples are provided to illustrate, but not
to limit the claimed invention.
Example 1
Materials and Methods
[0280] siRNA:
[0281] All siRNA used in these studies were chemically synthesized
by Protiva Biotherapeutics (Burnaby, BC), University of Calgary
(Calgary, AB) or Dharmacon Inc. (Lafayette, Colo.). siRNA were
desalted and annealed using standard procedures.
[0282] Lipid Encapsulation of siRNA:
[0283] Unless otherwise indicated, siRNAs were encapsulated into
liposomes composed of the following lipids; synthetic cholesterol
(Sigma, St. Louis, Mo.), the phospholipid DSPC
(1,2-distearoyl-sn-glycero-3-phosphocholine; Avanti Polar Lipids,
Alabaster, Ala.), the PEG-lipid PEG-cDMA (3-N-[(-Methoxy
poly(ethylene
glycol)2000)carbamoyl]-1,2-dimyrestyloxy-propylamine), and the
cationic lipid DLinDMA
(1,2-Dilinoleyloxy-3-(N,N-dimethyl)aminopropane) in the molar
ratios 48:10:2:40 respectively. In other words, unless otherwise
indicated, siRNA's were encapsulated in to lipsomes of the
following SNALP formulation: 2% PEG-cDMA, 40% DLinDMA, 10% DSPC,
48% cholesterol. For vehicle controls, empty liposomes with
identical lipid composition were formed in the absence of
siRNA.
[0284] Serum Nuclease Protection Assay:
[0285] Unmodified naked or lipid encapsulated siRNA (0.25 mg/ml)
were incubated in 50% mouse serum at 37.degree. C. At the times
indicated, aliquots were taken directly into gel loading buffer
containing 0.1% SDS and frozen in liquid nitrogen. After the final
timepoint, siRNA samples were run on a non-denaturing 20%
polyacrylamide TBE gel and visualized by ethidium bromide staining.
To confirm that nuclease protection of siRNA was conferred by lipid
encapsulation, 0.1% Triton-X100 was added to disrupt lipid bilayer
integrity immediately prior to incubation with serum.
[0286] RiboGreen.TM. Assay:
[0287] Equal volumes of diluted RiboGreen.TM. and SNALP are
combined so that the final concentration of siRNA is .about.167
ng/mL. 30 .mu.l of a 10% Triton X-100 solution is added to the
RiboGreen.TM./SNALP mixture and the resulting solution is incubated
at room temperature for at least 2 minutes. Fluorescence
measurements are taken at an appropriate wavelength before and
after the addition of triton X-100 to determine the amount of
encapsulated siRNA (see, e.g., Muriaux et al., PNAS USA 98(9):
5246-5251 (2001)).
[0288] In Vivo Cytokine Induction:
[0289] Animal studies were completed in accordance with the
Canadian Council on Animal Care guidelines following approval by
the local Animal Care and Use Committee at Protiva Biotherapeutics.
6-8 week old CD1 ICR mice (Harlan; Indianapolis, Ind.) were
subjected to a three week quarantine and acclimation period prior
to use. Encapsulated siRNA formulations were administered by
standard intravenous injection in the lateral tail vein in 0.2 ml
PBS. Blood was collected by cardiac puncture 6 h after
administration and processed as plasma for cytokine analysis. In
RNAi efficacy experiments, plasma was collected from 50 .mu.l test
bleeds 6 h after initial siRNA administration.
[0290] Cytokine ELISA:
[0291] All cytokines were quantified using sandwich ELISA kits
according to manufacturers instructions. These were mouse and human
IFN-.alpha. (PBL Biomedical; Piscataway, N.J.), human IL-6 and
TNF-.alpha. (eBioscience; San Diego, Calif.), and mouse IL-6,
TNF-.alpha., and IFN-.gamma. (BD Biosciences; San Diego, Calif.);
and Mouse IFN-.alpha. and IFN-.beta. (BD Biosciences, San Diego,
Calif.).
[0292] Cell Viability Assay:
[0293] Cell viability of in vitro cell cultures was assessed using
the commercial reagent CellTiter Blue (Promega Corp. Madison,
Wis.), a resazurin dye that is reduced by metabolically active
cells to the fluorogenic product resorufin. Various cancer cell
lines were cultured in vitro using standard tissue culture
techniques. 48-72 hours after treatment with siRNA formulations or
small molecule drugs, CellTiter Blue reagent was added to the
culture to quantify the metabolic activity of the cells--a measure
of cell viability.
[0294] Target mRNA Quantitation:
[0295] The QuantiGene branched DNA assay (Genospectra) was used to
quantify the reduction of target mRNA in cell cultures treated with
SNALP. Cell lysates were prepared according to the manufacturer's
instructions and used directly for Eg5 (kif11) and GAPDH mRNA
quantification. The ratio of Eg5 to GAPDH mRNA was calculated for
each cell culture and data expressed relative to the vehicle
treated control cells. Specific probe sets used for detection of
mRNA were designed by Genospectra to target the following regions:
for the Eg5 mRNA, positions 4188-4882 of accession NM.sub.--004523;
for GAPDH mRNA, positions 1-1303 of accession NM-002046.
[0296] Antibody Assay:
[0297] An ELISA was developed to detect IgM and IgG antibodies
against the PEG-lipid and other lipid components of SNALP using a
method described in Judge et al in Molecular Therapy (2006). 13(2)
pp. 328-337. 10 .mu.g of PEG-cDSA was added in 20 .mu.L 100%
ethanol to 96 well plates containing PVDF membranes (Millipore
Corp. Bedford, Mass.). PEG-cDSA coated membranes were allowed to
completely air dry for 2 hours before blocking for 1 h with 10% FBS
in PBS. 100 uL of serially diluted serum samples in blocking buffer
were then applied in duplicate wells for 1 h and washed 4 times
with 1% FBS in PBS. Plate bound antibodies were detected with
HRP-conjugated goat anti-IgM Fc.mu., or IgG Fc.gamma.. Bound enzyme
was developed with TMB substrate, stopped with 2N sulphuric acid,
then read in a spectrophotometer at 450 nm (minus 570 nm).
[0298] Apoptosis/Caspase 3/7 Assay
[0299] The level of Caspase 3 and 7 enzyme activity in siRNA
treated cells was assessed using the commercial reagent Apo-ONE
(Promega Corp. Madison, Wis.). This assay is based on the specific
enzymatic cleavage of the Caspase 3/7 substrate (Z-DEVD)2-Rhodamine
110 to a fluorogenic product and is used to quantify the level of
apoptosis in cultured cells. The relative level of Caspase 3/7
activity was assessed in a number of cancer cell lines at 24-48
hours after treatment with siRNA formulations.
Example 2
Selection of Candidate Eg5, EGFR or XIAP siRNA with Specificity to
Mouse and Human Targets
[0300] Candidate Eg5, EGFR or XIAP sequences were identified by
scanning Eg5 (Genbank Accession Nos. NM.sub.--004523 and
NM.sub.--010615), EGFR (Genbank Accession Nos. NM.sub.--005228 and
NM.sub.--207655), and XIAP (Genbank Accession Nos. NM.sub.--001167
and NM.sub.--009688) sequences to identify AA dinucleotide motifs
and the 19 nucleotides 3' of the motif. The following candidate
sequences were eliminated: (1) sequences comprising a stretch of 4
or more of the same base in a row; (2) sequences comprising
homopolymers of Gs; (3) sequences comprising triple base motifs
(GGG, CCC, AAA, or TTT); and (4) sequences comprising stretches of
7 or more G/Cs in a row.
[0301] Reynold's Rational Design criteria was then applied to the
remaining candidate sequences to identify sequences with 5 or more
of the following criteria:
1. 30%-52% GC content; 2. At least 3 A/Us at positions 15-19
(sense); 3. Absence of internal repeats; 4. A at position 19
(sense); 5. A at position 3 (sense); 6. U at position 10 (sense);
7. No G/C at position 19 (sense); and 8. No G at position 13
(sense).
[0302] Only results with a score of 6 or more in the Stockholm
rules (see, Chalk, Wahlestedt, and Sonnhammer method described in
Chalk et al., Biochem. Biophys. Res. Commun., 319:264-274 (2004))
were retained.
[0303] Next, sequences with a high score from, e.g., Classification
tree method or Chalk, Wahlestedt, and Sonnhammer method, were
retained.
[0304] Next, sequences with a score of 3 or more based on the rules
of Amarzguioui and Prydz, Biochem. Biophys. Res. Commun.,
316:1050-1058 (2004), were retained.
[0305] Next, sequences with thermodynamics >0 were
eliminated.
[0306] Finally, BLASTn was used to compare the sequences with the
mouse and human databases and sequences with homology to 15-16
contiguous by from the center of the target sequence (bp 3-18)
against any relevant gene were eliminated. The candidate sequences
are shown in Tables 1-9.
[0307] The candidate sequences are shown in Tables 1-9.
Example 3
siRNA Targeting the Kinesin Eg5 can Inhibit the Growth of Cancer
Cells
[0308] A panel of siRNA sequences, including Eg5 2263, were
evaluated for their antiproliferative effects against cancer cells.
Eg5 2263 was previously described in the literature (see, Weil et
al. 2002, BioTechniques 33:1244-1248) but the authors do not
describe its use as a therapeutic or anti-cancer agent. The RNAi
activity of the Eg5 siRNA panel were screened in vitro with HeLa
cells (human; FIG. 1) and Neuro2A cells (mouse; FIG. 2) using a
cell viability assay. The cells were treated with 1, 5, or 25 nM
siRNA complexed with lipofectamine. Viability of the cell cultures
were measured 48 h after treatment and expressed as mean
fluorescence units as shown in FIGS. 1 and 2.
Example 4
siRNA Formulated as SNALP are Potent Inhibitors of Cell Growth In
Vitro
[0309] Various Eg5 siRNAs were formulated as SNALP (SNALP
formulation: 2% PEG-cDMA, 40% DLinDMA, 10% DSPC, 48% cholesterol)
and evaluated for their inhibitory effects on cell growth in vitro.
The cells (i.e., Neuro2A cells) were treated with various SNALP
formulated Eg5 siRNAs, at different concentrations i.e. 3.1 nM, 6.3
nM, 12.5 nM, 25 nM and 50 nM, and their effect on cell viability
was evaluated (FIG. 3). Viability of cell cultures is expressed as
mean fluorescence units.
Example 5
Dose Dependent Silencing of Eg5 mRNA in Human HepG2 Cell by Eg5
SNALP
[0310] Human hepatocellular HepG2 cells were treated with either
Eg5 2263 SNALP (SNALP formulation: 2% PEG-cDMA, 40% DLinDMA, 10%
DSPC, 48% cholesterol) or control (i.e., a non-targeting siRNA)
SNALP. Eg5 mRNA levels were measured after 48 h by a branched DNA
assay. The results are shown in FIG. 4: Top Panel--Eg5:GAPD mRNA
ratios; Bottom panel--% knockdown of Eg5 mRNA versus non-treated
cells. The results confirm that the potent effects of Eg5 SNALP on
cell viability is due to the silencing of Eg5 RNA.
Example 6
Cell Phenotype Changes Following Treatment with Eg5 siRNA
[0311] Control siRNA treated HeLa cells and Eg5 siRNA treated HeLa
cells were analyzed by immunohistological staining (DAPI (DNA),
blue; tubulin, green). The staining results showed that the control
cells demonstrated typical mitotic phenotypes, while the Eg5 siRNA
treated HeLa cells induced aberrant cell mitosis characterized by
monoastral spindle formation due to Eg5 inhibition (FIG. 5).
Example 7
Anti-Proliferative Activity of Chemically Modified Eg5 2273
siRNA's
[0312] A panel (8 total) of 2'-OMe modified siRNAs of Eg5 2263
siRNA sequence was prepared and their RNAi activity was evaluated
in HeLa human cells or Neuro2A mouse cells. The modifications
involved introducing 2'-OMe guanosine or 2'-OMe uridine at selected
positions in the sense or antisense strand the sequence
modification are shown in (FIG. 6). The modified Eg5 2263 siRNAs
incorporated less than 20% of chemically modified nucleosides.
Anti-proliferative activity was evaluated in a cell viability
bioassay (FIG. 7, HeLa human cells; and FIG. 8 Neuro2A mouse
cells). Cell viability of cell cultures was measured 48 hours after
treatment and expressed as mean fluorescence units.
Example 8
In Vivo Cytokine Induction by Chemically Modified Eg5 2263
SNALP
[0313] Unmodified Eg5 2263 siRNA and certain 2'-OMe modified
variants thereof (i.e., U/O, G/O, U/U and G/G) were formulated into
SNALP (SNALP formulation: 2% PEG-cDMA, 40% DLinDMA, 10% DSPC, 48%
cholesterol). These SNALP formulations were tested in vivo in to
look for the induction of an immune response, e.g., cytokine
induction. Balb/c mice (n=3/treatment group) were injected with 40
ug of the SNALP formulation and samples were collected 6 h post
treatment with SNALP and tested for Interferon-alpha by ELISA
assay. The results show that 2'-OMe modifications to Eg5 2263 siRNA
abrogate Interferon induction associated with systemic
administration of the native (unmodified) duplex (FIG. 9).
Example 9
Antibody Response Against the Delivery Vehicle for siRNA with
Selectively 2'-OMe Modified Eg5 2263
[0314] Unmodified Eg5 2263 siRNA and a 2'-OMe modified variant
thereof (i.e., Eg5 2263 U/U siRNA) were formulated into SNALP
(SNALP formulation: 2% PEG-cDMA, 40% DLinDMA, 10% DSPC, 48%
cholesterol) and tested in vivo in mice (protocol: 3.times.2 mg/kg
daily; serum assayed on day 10) to look for the induction of an
immune response against the delivery vehicle (PEG). The results
show that selective 2'-OMe modification to Eg5 2263 siRNA (e.g. U/U
modified) abrogates the antibody response against the delivery
vehicle that is associated with systemic administration of the
native (unmodified) duplex. (FIG. 10). In FIG. 10, the top panel
show PEG antibody levels in individual mice treated with unmodified
Eg5 SNALP or with U/U modified Eg5 SNALP.
Example 10
The Anti-Cancer Activity of Eg5 U/U SNALP in a Range of Cancer Cell
Lines
[0315] The anti-cancer activity of Eg5 U/U SNALP was demonstrated
against a range of cancer cell lines. Activity against the cell
lines was monitored by a cell viability assay, and by an apoptosis
assay as measured by Caspase 3/7 activation. Eg5 U/U SNALP
specificity is confirmed by comparison with control SNALP
containing non-targeting siRNA. FIG. 11 illustrates a decrease in
cell viability in all cell lines tested after treatment with Eg5
U/U SNALP as compared to control. Upper left panel: LS174T human
colorectal adenocarcinoma; Upper right panel: HT29 human colorectal
adenocarcinoma; lower left panel: HepG2 human hepatocellular
carcinoma; Lower right panel; Neuro2A murine Neuroblastoma. The
induction of apoptosis by Eg5 SNALP U/U modified siRNA, as measured
by Caspase 3/7 activity, was measured in human hepatocellular
carcinoma cells and human colorectal cancer cells after 24 hours
and after 48 hours. The Caspase 3/7 activity is expressed as fold
induction over media only treated cells. FIG. 12 illustrates that
apoptosis induction in human hepatocarcinoma cells is increased in
Eg5 2263 U/U SNALP as compared to control siRNA. FIG. 13
illustrates that apoptosis induction is increased in Eg5 2263 U/U
SNALP in human colorectal cancer cells (HT-29 and LS 174T) as
compared to control.
Example 11
Comparison Between Eg5 2263 U/U SNALP Vs. Small Molecule Eg5
Inhibitor Drug
[0316] There are currently several small molecule Eg5 inhibitors
under clinical evaluation. Recent publications indicate that
certain cancer cell lines (e.g., HT-29 colorectal adenocarcinoma
cells) are resistant to apoptosis induction by small molecule Eg5
inhibitors. A comparison of apoptosis activity, via a comparison of
Caspase 3/7 induction activity, in HT-29 colorectal adenocarcinoma
cells (a small molecule Eg5 inhibitor resistant cell type) after
treatment with a small molecule Eg5 inhibitor (i.e, Monastrol at 50
or 100 uM concentration), or with Eg5 2263 U/U SNALP (at 25 or 50
nM concentration) demonstrates that cells lines that are resistant
to small molecule Eg5 inhibitors are highly sensitive to Eg5 SNALP
(FIG. 14). A comparison of Eg5 2263 U/U SNALP with the small
molecule Eg5 inhibitor, monastrol, in the inhibition of various
cancer cell lines, as measure by cell viability assays,
demonstrates that Eg5 2263 U/U SNALP is superior at inhibiting cell
growth in these cancer cell lines than monastrol (FIG. 15). The
results of these experiments shows that SNALP can confer advantages
over conventional small molecule drugs as anti-cancer agents.
Example 12
Serum Nuclease Protection Assay
[0317] Naked Eg5 siRNA and SNALP encapsulated Eg5 siRNA were
subjected to serum nuclease degredation. The result in the serum
nuclease protection assay (presented in FIG. 16) shows that SNALP
encapsulation provide the protection from serum nuclease required
for in vivo use of siRNA.
Example 13
In Vivo Activity of Eg5 SNALP in Tumor Bearing Mice
[0318] Anti-tumor effects of Eg5 2263 U/U SNALP (2% PEG-cDSA, 40%
DLinDMA, 10% DSPC, 48% cholesterol), as compared to SNALP
containing control siRNA (Luc), was evaluated in a subcutaneous
model in mice. A/J mice bearing s.c. Neuro2A tumors were treated
with SNALP at 5.times.2 mg/kg daily (d6-10) by i.v. administration.
Tumors were measured by calipers and recorded as tumor volume. The
results of this study demonstrates that Eg5 2263 U/U SNALP exerts a
specific anti-tumor effect in a s.c. tumor model (FIG. 17).
Additionally, therapeutic dosing is well tolerated in tumor-bearing
mice (FIG. 18).
Example 14
In Vivo Activity of Eg5 SNALP in Tumor Bearing Mice
[0319] Anti-tumor effects of Eg5 2263 U/U SNALP (2% PEG-cDMA, 40%
DLinDMA, 10% DSPC, 48% cholesterol), as compared to SNALP
containing control siRNA (Luc), was evaluated in an intrahepatic
tumor model in mice. In this study, A/J mice were seeded with
100,000 Neuro2A cells by intrahepatic injection. On day 12, the
mice were treated with Eg5 2263 U/U SNALP (n=6) or control siRNA
(Luc SNALP; n=5). The mice were dosed at 3 mg/kg at t=0 h and at
t=6 h, for a cumulative dosage of 6 mg/kg. The livers were
collected 30 h after the first dose (d13), and formalin-fixed for
conventional histology. The tissues were processed and stained with
H&E. Tumor histology showed that Eg5 2263 U/U SNALP treated
mice induced extensive phenotypic changes (e.g., aberrant mitosis
and apoptosis) in the intrahepatic tumor cells, which is
characteristic of Eg5 inhibition, as compared to control treated
subjects. FIG. 19 shows the tumor histopathology of the
intrahepatic Neuro2A tumor that was treated with Eg5 2263 U/U
SNALP. Histology shows numerous tumor cells with atypical mitotic
figures and apoptotic bodies characteristic of Eg5 inhibition. FIG.
20 shows the tumor histopathology of the intrahepatic Neuro2A tumor
that was treated with control SNALP. Histology results shows
numerous tumor cells with normal mitotic figures.
Example 15
In Vitro Activity of EGFr siRNA
[0320] A431 carcinoma cells were treated with increasing
concentrations of lipofectamine complexed EGFr or non-targeting
control siRNA. EGFr mRNA levels were quantitated by branched DNA
assay after 48 h culture. EGFr mRNA values are expressed as % of
media treated cells. As shown in FIG. 30, EGFr sequences 817 and
1252 and 1986 displayed the greatest levels of mRNA silencing.
[0321] Cell viability was also quantitated by CellTiter Blue
fluorescence assay after 48 h culture. iability scores are
expressed as % of media treated cells. As shown in FIG. 31, EGFr
sequences 817 and 1252 and 1986 that displayed the greatest levels
of mRNA silencing also show the most significant effects on cell
viability.
Example 16
In Vitro Activity of EGFr siRNA
[0322] HT-29 tumor cells were treated with increasing
concentrations of EGFr sequences 817 and 1252 and 1986 siRNA
sequences or a non-targeting control siRNA formulated in SNALP.
EGFr mRNA levels were measured 48 h after SNALP treatment by bDNA
assay. As shown in FIG. 32, EGFr sequences 817 and 1252 and 1986
siRNA formulated in SNALP silence EGFR siRNA.
Example 17
In Vitro Activity of XIAP SNALP
[0323] SNALP containing XIAP-113, XIAP-300 or non-targeting control
siRNA were applied to HT-29 cells in vitro at various
concentrations. 48 h later, XIAP mRNA levels were measured by bDNA
assay and expressed as % of media treated cells. As shown in FIG.
33, XIAP-113 SNALP causes significant, dose-dependent decreases in
XIAP mRNA levels
Example 18
In Vitro Activity of XIAP SNALP
[0324] SNALP containing XIAP-113, XIAP-300 or non-targeting control
siRNA were applied to LS174T colon adenocarcinoma cells in vitro at
35 nM siRNA. Cells were then treated with monastrol, a small
molecule inhibitor of Eg5. Viability of cell cultures was assessed
after 48 h. As shown in FIG. 34, XIAP-113 and -300 SNALP sensitize
human colon cancer cells to the cytotoxic effects of the Eg5
inhibitor. Degree of sensitization correlates with the relative
potency of mRNA silencing by these SNALP
Example 19
In Vitro Activity of Eg5 SNALP in Combination with XIAP SNALP
[0325] HT29 colon cancer cells were co-cultured with 10 nM or 30 nM
XIAP-113 SNALP plus increasing concentrations of Eg5 2263 SNALP.
Cell viability and caspase 3/7 activity were assayed after 48 h
culture. As shown in FIG. 35, co-administration of XIAP SNALP
sensitizes HT29 cells to killing by Eg5 SNALP, as demonstrated by
significant increases in the level of apoptosis and corresponding
decrease in cell viability in the cultures.
[0326] It is to be understood that the above description is
intended to be illustrative and not restrictive. Many embodiments
will be apparent to those of skill in the art upon reading the
above description. The scope of the invention should, therefore, be
determined not with reference to the above description, but should
instead be determined with reference to the appended claims, along
with the full scope of equivalents to which such claims are
entitled. The disclosures of all articles and references, including
patent applications, patents, PCT publications, and Accession Nos.
are incorporated herein by reference for all purposes.
Sequence CWU 0 SQTB SEQUENCE LISTING The patent application
contains a lengthy "Sequence Listing" section. A copy of the
"Sequence Listing" is available in electronic form from the USPTO
web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20140161894A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
0 SQTB SEQUENCE LISTING The patent application contains a lengthy
"Sequence Listing" section. A copy of the "Sequence Listing" is
available in electronic form from the USPTO web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20140161894A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
* * * * *
References